USPatent applicationPatented

Pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural bactericides

Granted 10 Jun 2003 · 2 office actions

Application· this page
9830578
filed 8 May 2001
Publication
Not published
not published
Patent
US 6,576,631
granted 10 Jun 2003

Life of the application

8 dated events
⤢ drag to zoom20002002200420062008201020122014201620182020ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

A pyrimidinylbenzimidazole or triazinylbenzimidazole derivative represented by the general formula (I): wherein A is N or CR3, and R1, R2, R3, X, Y and n are as defined in the disclosure.

Description

12 parts
›TECHNICAL FIELD

The present invention relates to novel pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural fungicides containing said derivatives as the active ingredients.

›BACKGROUND ART

As compounds related to the pyrimidinylbenzimidazole derivatives of the present invention, 4-aminopyrimidine derivatives disclosed as pharmaceuticals in U.S. Pat. No. 5,525,604 and European Patent No. 640,599 and pyrimidine derivatives disclosed as herbicides in International Publication No. WO94/17059, are mentioned, but no disclosure regarding agricultural/horticultural fungicides has been made. French Patent No. 1,476,529 discloses benzimidazolyl sulfonamide derivatives having insecticidal and fungicidal activities, but no disclosure regarding the present compounds has been made. Further, as compounds related to the triazinylbenzimidazole derivatives of the present invention, triazine derivatives disclosed in JP-A-47-36837, JP-A-49-17677 and Kogyo Kagaku Zassi (Journal of Industrial Chemistry) vol 73, No. 5, p1000 (1970) as coloring agents for textile goods, may be mentioned, but no disclosure regarding agricultural/horticultural fungicides has been made. Further, anilinopyrimidine derivatives as production intermediates therefor have not been known.

The present invention provides novel pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives and agricultural/horticultural fungicides containing them as the active ingredients.

The present inventors have conducted extensive studies to create novel agricultural/horticultural fungicides and as a result, found that the pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives of the present invention (hereinafter referred to as compounds of the present invention) are novel compounds which are not disclosed in any literatures and have outstanding effects as agricultural/horticultural fungicides, and the present invention has been accomplished.

›DISCLOSURE OF THE INVENTION · 1 of 5

Namely, the present invention resides in a pyrimidinylbenzimidazole or triazinylbenzimidazole derivative represented by the general formula [I]:

wherein A is N or CR 3 , each of R 1 and R 2 which are independent of each other, is a hydrogen atom, a halogen atom, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 3 -C 6 ) cycloalkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 3 -C 6 ) cycloalkoxy group, a (C 1 -C 4 ) haloalkoxy group, a cyano (C 1 -C 4 ) alkyloxy group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyloxy group, a (C 3 -C 6 ) cycloalkyl (C 1 -C 4 ) alkoxy group, a benzyloxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 6 ) alkylthio group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a phenoxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 4 ) alkylcarbonyl group, a formyl group, a phenyl group, a di(C 1 -C 4 ) alkylamino group, a cyano group or a (C 1 -C 6 ) alkylsulfonyl group, R 3 is a hydrogen atom, a (C 1 -C 6 ) alkyl group, a (C 1 -C 6 ) alkoxy group or a halogen atom, X is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 3 -C 6 ) cycloalkyl group, a benzyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 1 -C 6 ) alkylthio group, a (C 1 -C 6 ) alkylsulfonyl group, a phenoxy group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 4 ) haloalkoxy group, a (C 1 -C 4 ) alkylcarbonyl group, a (C 1 -C 4 ) alkoxycarbonyl group, an amino group, a mono(C 1 -C 4 ) alkylamino group, a di(C 1 -C 4 ) alkylamino group, an anilino group or a phenyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], Y is a halogen atom, a nitro group, a cyano group, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 1 -C 4 ) haloalkoxy group, a (C 1 -C 6 ) alkylthio group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 4 ) alkylcarbonyl group, a (C 1 -C 4 ) alkoxycarbonyl group, a benzoyl group, an amino group, a mono(C 1 -C 4 ) alkylamino group, a di(C 1 -C 4 ) alkylamino group, a phenyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group] or a phenoxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], and n is 0 or an integer of from 1 to 3}, an anilinopyrimidine or anilinotriazine derivative, as an intermediate therefor, represented by the general formula [XV]:

(wherein A is N or CR 3 , each of R 1 and R 2 which are independent of each other, is a hydrogen atom, a halogen atom, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 3 -C 6 ) cycloalkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 3 -C 6 ) cycloalkoxy group, a (C 1 -C 4 ) haloalkoxy group, a cyano (C 1 -C 4 ) alkyloxy group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyloxy group, a (C 3 -C 6 ) cycloalkyl (C 1 -C 4 ) alkoxy group, a benzyloxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 6 ) alkylthio group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a phenoxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 4 ) alkylcarbonyl group, a formyl group, a phenyl group, a di(C 1 -C 4 ) alkylamino group, a cyano group or a (C 1 -C 6 ) alkylsulfonyl group, R 3 is a hydrogen atom, a (C 1 -C 6 ) alkyl group, a (C 1 -C 6 ) alkoxy group or a halogen atom, R 5 is an amino group, a nitro group or —NHCOX, X is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 3 -C 6 ) cycloalkyl group, a benzyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 2 -C 6 ) alkylthio group, a (C 1 -C 6 ) alkylsulfonyl group, a phenoxy group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 4 ) haloalkoxy group, a (C 1 -C 4 ) alkylcarbonyl group, a (C 1 -C 4 ) alkoxycarbonyl group, an amino group, a mono(C 1 -C 4 ) alkylamino group, a di(C 1 -C 4 ) alkylamino group, an anilino group or a phenyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], Y is a halogen atom, a nitro group, a cyano group, a (C 1 -C 6 ) alkyl group, a (C 2 -C 6 ) alkenyl group, a (C 2 -C 6 ) alkynyl group, a (C 1 -C 6 ) alkoxy group, a (C 2 -C 6 ) alkenyloxy group, a (C 2 -C 6 ) alkynyloxy group, a (C 1 -C 4 ) haloalkoxy group, a (C 1 -C 6 ) alkylthio group, a (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group, a (C 1 -C 4 ) haloalkyl group, a (C 1 -C 4 ) alkylcarbonyl group, a (C 1 -C 4 ) alkoxycarbonyl group, a benzoyl group, an amino group, a mono(C 1 -C 4 ) alkylamino group, a di(C 1 -C 4 ) alkylamino group, a phenyl group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group] or a phenoxy group [said group may be substituted by a halogen atom, a (C 1 -C 4 ) alkyl group or a (C 1 -C 4 ) alkoxy group], and n is 0 or an integer of from 1 to 3}, and an agricultural/horticultural fungicide containing the pyrimidinylbenzimidazole or triazinylbenzimidazole derivative as the active ingredient.

›DISCLOSURE OF THE INVENTION · 2 of 5

Now, the symbols and terms used in the present specification will be explained below.

The halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

A notation such as (C 1 -C 6 ) indicates that the carbon number of a substituent following this notation is from 1 to 6 in this case.

The (C 1 -C 6 ) alkyl group is a linear or branched alkyl group and may, for example, be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl or 3,3-dimethylbutyl.

The (C 3 -C 6 ) cycloalkyl may, for example, be cyclopropyl, cyclopentyl or cyclohexyl.

The (C 1 -C 4 ) haloalkyl group is a linear or branched alkyl group substituted by a halogen atom and may, for example, be fluoromethyl, chloromethyl, difluoromethyl, dichloromethyl, trifluoromethyl or pentafluoroethyl.

The (C 2 -C 6 ) alkenyl group is a linear or branched alkenyl group and may, for example, be vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl or 2-butenyl.

The (C 2 -C 6 ) alkynyl group is a linear or branched alkynyl group and may, for example, be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 4-methyl-1-pentynyl or 3-methyl-1-pentynyl.

The (C 1 -C 6 ) alkoxy group is an alkyloxy group wherein the alkyl moiety has the above meaning and may, for example, be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy or n-hexyloxy.

The (C 2 -C 6 ) alkenyloxy group is an alkenyloxy group wherein the alkenyl moiety has the above meaning, and may, for example, be allyloxy, isopropenyloxy or 2-butenyloxy.

The (C 2 -C 6 ) alkynyloxy group is an alkynyloxy group wherein the alkynyl moiety has the above meaning, and may, for example, be 2-propynyloxy, 2-butynyloxy or 3-butynyloxy.

The (C 3 -C 6 ) cycloalkoxy group is a cycloalkyloxy group wherein the cycloalkyl moiety has the above meaning, and may, for example, be cyclopropyloxy, cyclopentyloxy or cyclohexyloxy.

The (C 1 -C 4 ) haloalkoxy group is a haloalkyloxy group wherein the haloalkyl moiety has the above meaning, and may, for example, be fluoromethoxy, difluoromethoxy, trifluoromethoxy or pentafluoroethoxy.

The (C 1 -C 6 ) alkylthio group is an alkylthio group wherein the alkyl moiety has the above meaning, and may, for example, be methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio or n-hexylthio.

The (C 3 -C 6 ) cycloalkyl (C 1 -C 4 ) alkoxy group may, for example, be cyclopropylmethyloxy, cyclopentylmethyloxy or cyclohexylmethyloxy.

The (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl group is a group wherein the alkyl moiety and the alkoxy moiety have the above meanings, and may, for example, be a group such as methoxymethyl, ethoxymethyl, isopropoxymethyl, pentyloxymethyl, methoxyethyl or butoxyethyl.

The (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyloxy group is a group wherein the alkyl moiety and the alkoxy moiety have the above meanings, and may, for example, be a group such as methoxymethyloxy, ethoxymethyloxy, isopropoxymethyloxy, pentyloxymethyloxy, methoxyethyloxy or butoxyethyloxy.

The cyano (C 1 -C 4 ) alkyloxy group is a group wherein the alkyl moiety has the above meaning, and may, for example, be a group such as cyanomethyloxy, cyanoethyloxy or cyanopropyloxy.

The (C 1 -C 4 ) alkylcarbonyl group is an alkylcarbonyl group wherein the alkyl moiety has the above meaning, and may, for example, be a group such as acetyl, propionyl, butyryl, isobutyryl, pivaloyl or hexanoyl.

The (C 1 -C 4 ) alkoxycarbonyl group is an alkoxycarbonyl group wherein the alkoxy moiety has the above meaning, and may, for example, be methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, n-pentyloxycarbonyl or n-hexyloxycarbonyl.

The mono (C 1 -C 4 ) alkylamino group is a monoalkylamino group wherein the alkyl moiety has the above meaning, and may, for example, be methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butylamino or n-hexylamino.

The di (C 1 -C 4 ) alkylamino group may, for example, be dimethylamino, diethylamino, dipropylamino or dibutylamino.

The (C 1 -C 6 ) alkylsulfonyl group is an alkylsulfonyl group wherein the alkyl moiety has the above meaning, and may, for example, be methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl or n-hexylsulfonyl.

Now, specific examples of the compounds of the present invention represented by the general formula [I] will be disclosed in Tables 1 to 35. However, the compounds of the present invention are not limited to such compounds. Here, the compound numbers will be referred to in the subsequent description.

Symbols in the Tables have the following meanings respectively. Me represents methyl, Et represents ethyl, Pr represents n-propyl, Pr-i represents isopropyl, Bu represents n-butyl, Pr-c represents cyclopropyl, Pn-c represents cyclopentyl, Ph represents phenyl, and Bn represents benzyl. Further, Ph(2-Cl) represents 2-chlorophenyl, and Bn(4-Cl) represents 4-chlorobenzyl, for example.

Typical processes for producing pyrimidinylbenzimidazole and triazinylbenzimidazole derivatives represented by the general formula [I] as the compounds of the present invention, will be exemplified below.

(wherein X, Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively, and L is a leaving group such as a halogen atom, a (C 1 -C 6 ) alkylsulfonyl group or a benzylsulfonyl group.)

The compound of the present invention represented by the general formula [I] can be produced by reacting a benzimidazole derivative represented by the general formula [II] and a pyrimidine derivative or triazine derivative represented by the general formula [III] in the presence of a base in a solvent. Here, as the base, a carbonate, hydrogencarbonate, acetate, alcoholate, hydroxide, hydride or oxide of an alkali metal or alkaline earth metal, particularly sodium, potassium, magnesium or calcium, may, for example, be used. The solvent which can be used in the present reaction may be one which does not inhibit the progress of the present reaction, and an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, monoglyme or diglyme, a halogenated hydrocarbon such as dichloroethane, chloroform, carbon tetrachloride or tetrachloroethane, an aromatic hydrocarbon such as benzene, chlorobenzene, nitrobenzene or toluene, or N,N-dimethylformamide, N,N-dimethylacetoamide, 1,3-dimethyl-2-imidazolinone or dimethylsulfoxide, may, for example, be used. These inert solvents may be used alone or as mixed. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the inert solvent to be used, and preferably within a range of from 0° C. to 80° C. The reaction time varies depending upon e.g. the reaction temperature and the reaction amount, but may be selected within a range of from 1 hour to 48 hours in general. After completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

›DISCLOSURE OF THE INVENTION · 3 of 5

Here, the benzimidazole derivative represented by the general formula [II] may be a commercially available product or may be produced by a known method [e.g. a method as disclosed in Angewandte Chemie, vol 85, p866 (1973); Journal of the American Chemical Society, vol 69, p2459 (1947); Journal of the American Chemical Society, vol 82, p3138 (1960); Organic Syntheses, vol 2, p65 (1943); or Organic Syntheses, vol 4, p569 (1963)].

(wherein X, Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively.)

The anilide derivative represented by the general formula [V] can be produced by reacting an anilinopyrimidine derivative or anilinotriazine derivative represented by the general formula [IV] with an acylating agent in an inert solvent. The reaction is carried out preferably in the presence of a base. As the acylating agent, an acid halide such as acetyl chloride, propionyl chloride or benzoyl chloride, or an acid anhydride such as trifluoroacetic anhydride, propionic anhydride or benzoic anhydride may be mentioned. The inert solvent which can be used in the present reaction may be one which does not inhibit the progress of the present reaction, and for example, e.g. a ketone such as acetone, methyl ethyl ketone or cyclohexanone, an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, monoglyme or diglyme, an ester such as ethyl acetate or methyl acetate, a halogenated hydrocarbon such as dichloroethane, chloroform, carbon tetrachloride or tetrachloroethane, an aromatic hydrocarbon such as benzene, chlorobenzene, nitrobenzene or toluene, a nitrile such as acetonitrile, or N,N-dimethylformamide, N,N-dimethylacetoamide, 1,3-dimethyl-2-imidazolinone, dimethylsulfoxide, pyridine or water, may be used. These inert solvents may be used alone or as mixed. As the base to be used in the present reaction, an inorganic base or an organic base may be used. For example, as an inorganic base, a carbonate or hydroxide of an alkali metal or alkaline earth metal, such as sodium carbonate, potassium carbonate, calcium carbonate, sodium hydrogencarbonate, sodium hydroxide, potassium hydroxide or calcium hydroxide, or a hydride of an alkali metal such as lithium hydride or sodium hydride, may be used, and as an organic base, triethylamine, diisopropylethylamine or pyridine may, for example, be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the inert solvent to be used, and preferably within a range of from 0° C. to 50° C. The reaction time varies depending upon e.g. the reaction temperature and the reaction amount, but may be selected within a range of from several minutes to 48 hours in general.

Then, the anilide derivative represented by the general formula [V] is subjected to a cyclization reaction without a solvent or in a solvent, in the presence of a catalyst as the case requires, to produce the compound of the present invention represented by the general formula [I]. As the catalyst to be used here, an inorganic acid such as sulfuric acid or hydrochloric acid or an organic acid such as para-toluenesulfonic acid may, for example, be used. As the solvent which can be used in the present reaction, the solvent exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from 0° C. to the boiling point of the solvent to be used, and preferably within a range of from room temperature to the boiling point of the solvent. The reaction time varies depending upon e.g. the reaction temperature and the reaction amount, but may be selected within a range of from 1 hour to 48 hours in general. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein X, Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively.)

The compound of the present invention represented by the general formula [I] can be produced directly by heating an anilinopyrimidine derivative or anilinotriazine derivative represented by the general formula [IV] in a carboxylic acid represented by the general formula [VI], in the presence of an acid anhydride as the case requires. The reaction temperature may be selected within a range of from 0° C. to the boiling point of the carboxylic acid to be used, preferably within a range of from room temperature to the boiling point of the carboxylic acid. The reaction time may be selected within a range of from 1 hour to 48 hours in general. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively.)

The compound represented by the general formula [I-a] can be produced by reacting an anilinopyrimidine derivative or anilinotriazine derivative represented by the general formula [IV] and a reagent [VII] such as BrCN or H 2 NCN by a method known from a literature [e.g. a method as disclosed in Journal of the American Chemical Society, vol 69, p2459 (1947); or Angewandte Chemie, vol 85, p866 (1973)] in a solvent. As the solvent which can be used in the present reaction, the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from 0° C. to the boiling point of the reaction mixture. The reaction time varies depending upon e.g. the reaction temperature or the reaction amount, and may be selected within a range of from 1 hour to 48 hours in general. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

›DISCLOSURE OF THE INVENTION · 4 of 5

(wherein X′ is a halogen atom, and Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively.)

The compound represented by the general formula [I-d] can be produced by diazotizing a 2-aminobenzimidazole derivative represented by the general formula [I-a] by a known method [e.g. Sandmeyer method, Schwechten method or Gattermann method] in a solvent at a reaction temperature which are conventionally employed, followed by halogenation. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively, and R 4 is a C 1 -C 6 alkyl group.)

The compound represented by the general formula [I-e] can be produced by oxidizing a pyrimidinylbenzimidazole derivative or triazinylbenzimidazole derivative represented by the general formula [I-b] by a known method. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires. The oxidizing agent which can be used in the present reaction may, for example, be hydrogen peroxide or an organic peracid such as m-chloroperbenzoic acid. As the solvent which can be used, the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from 5° C. to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein Y, R 1 , R 2 , A, L and n have the same meanings as mentioned above respectively, and X″ is a (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynyloxy, (C 1 -C 6 ) alkylthio or (C 1 -C 6 ) alkylamino group.)

The compound of the present invention represented by the general formula [I-f] can be produced by reacting a pyrimidinylbenzimidazole derivative or triazinylbenzimidazole derivative represented by the general formula [I-c] and an alcohol, mercaptan or amine represented by the general formula [XVI] in the presence of a base without a solvent or in a solvent. As the base and the solvent which can be used in the present reaction, the base and the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from room temperature to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein X, Y, A, L and n have the same meanings as mentioned above respectively, and Z is a (C 1 -C 6 ) alkoxy, (C 2 -C 6 ) alkenyloxy, (C 2 -C 6 ) alkynloxy, (C 1 -C 6 ) alkylthio or di (C 1 -C 6 ) alkylamino group.)

The compound of the present invention represented by the general formula [I-h] can be produced by reacting a pyrimidinylbenzimidazole derivative or triazinylbenzimidazole derivative represented by the general formula [I-g] and an alcohol, mercaptan or amine represented by the general formula [VIII] in the presence of a base without a solvent or in a proper solvent. As the base and the solvent which can be used in the present reaction, the base and the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from room temperature to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

(wherein Y, R 1 , R 2 , A and n have the same meanings as mentioned above respectively.)

The compound of the present invention represented by the general formula [I-i] can be produced by reducing an anilinotriazine derivative represented by the general formula [IX] with iron powder in acetic acid or in a mixed solvent of acetic anhydride and acetic acid. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from room temperature to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

Now, processes for synthesizing the production intermediates for the compounds of the present invention will be explained in detail below.

Process 10

Synthesis of Production Intermediate Represented by the General Formula [IV]

The compound [IV] may be synthesized, for example, in accordance with the following process, but the process is not limited thereto.

(wherein Y, R 1 , R 2 , A, L and n have the same meanings as mentioned above respectively.)

A formanilide derivative represented by the general formula [X] and a pyrimidine derivative or triazine derivative represented by the general formula [III] are reacted in the presence of a base in an inert solvent at a reaction temperature within a range of from −20° C. to the boiling point of the solvent, preferably within a range of from room temperature to 80° C., followed by hydrolysis with e.g. an acid such as hydrochloric acid, hydrobromic acid or sulfuric acid or an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide by a generally known method to obtain [XI]. Then, the obtained [XI] is reduced with a reducing agent such as iron, tin chloride, or a hydrogen atom accompanied with another catalyst such as palladium carbon or Raney Nickel, by a generally known method to produce an anilinopyrimidine derivative or anilinotriazine derivative represented by the general formula [IV].

›DISCLOSURE OF THE INVENTION · 5 of 5

Process 11

Synthesis of Production Intermediate Represented by the General Formula [XI-b]

The compound [XI-b] may be synthesized, for example, in accordance with the following process, but the process is not limited thereto.

(wherein Y, Z and n have the same meanings as mentioned above respectively.)

A nitroaniline derivative represented by the general formula [XII] and cyanuric chloride represented by [XIII] are reacted in the presence of a base without a solvent or in a proper solvent to produce an anilinotriazine derivative represented by the general formula [XI-a], which is successively reacted with an alcohol, mercaptan or amine represented by the general formula [VIII] in the presence of a base without a solvent or in a proper solvent to produce an anilinotriazine derivative represented by the general formula [XI-b]. As the base and the solvent which can be used in the present reaction, the base and the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from room temperature to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

Process 12

Synthesis of Production Intermediates Represented by the General Formulae [XI-c] and [XI-d]

The compounds [XI-c] and [XI-d] may be synthesized, for example, in accordance with the following process, but the process is not limited thereto.

(wherein R 1 , Y, L, Z and n have the same meanings as mentioned above respectively.)

A formanilide derivative represented by the general formula [X] and a triazine derivative represented by [XIV] are reacted in the presence of a base without a solvent or in a proper solvent, followed by hydrolysis with e.g. an acid such as hydrochloric acid, hydrobromic acid or sulfuric acid or an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, by a generally known method to produce an anilinotriazine derivative represented by the general formula [XI-c], which is successively reacted with an alcohol, mercaptan or amine represented by the general formula [VIII] in the presence of a base without a solvent or in a proper solvent to produce an anilinotriazine derivative represented by the general formula [XI-d]. As the base and the solvent which can be used in the present reaction, the base and the solvent as exemplified in Process 1 may be used. The reaction temperature may be selected within a range of from −20° C. to the boiling point of the reaction mixture to be used, preferably within a range of from room temperature to the boiling point of the reaction mixture. After the completion of the reaction, the desired product is isolated from the reaction system by a conventional method and may be purified by e.g. column chromatography or recrystallization, as the case requires.

Here, the anilinopyrimidine and anilinotriazine derivatives represented by the general formulae [IV], [V] and [XI] are also novel compounds, and specific examples in thereof will be disclosed in Tables 36 to 65.

›BEST MODE FOR CARRYING OUT THE INVENTION · 1 of 4

Now, the processes for producing the compound of the present invention, formulation methods and applications will be specifically described with reference to Examples.

PREPARATION EXAMPLE 1

1-(4-methoxypyrimidin-2-yl)-benzimidazole (Compound Number I-667)

Benzimidazole (0.50 g) was dissolved in dimethylformamide (10 ml), and sodium hydride (60% purity, oily) (0.18 g) was added thereto at room temperature. After stirring for 1 hour, 2-chloro-4-methoxypyrimidine (0.62 g) was added at room temperature, followed by stirring for 3 hours. Ice water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.40 g of the desired product as a white powder (m.p. 114-116° C.).

PREPARATION EXAMPLE 2

1-(4,6-Dimethoxypyrimidin-2-yl)-2-methylthiobenzimidazole (Compound Number I-4)

2-Methylthiobenzimidazole (0.50 g) was dissolved in dimethylformamide (10 ml), and sodium hydride (60% purity, oily) (0.13 g) was added thereto at room temperature. After stirring for 1 hour, 2-methylsulfonyl-4,6-dimethoxypyrimidine (0.67 g) was added at room temperature, followed by stirring for 8 hours. Ice water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.80 g of the desired product as a white powder (m.p. 135-137° C.)

PREPARATION EXAMPLE 3

1-(4,6-Dimethoxypyrimidin-2-yl)-2-methylsulfonylbenzimidazole (Compound Number I-5)

1-(4,6-dimethoxypyrimidin-2-yl)-2-methylthiobenzimidazole (0.70 g) and m-chloroperbenzoic acid (1.30 g) were dissolved in chloroform (30 ml), followed by stirring at room temperature for 3 hours. The reaction liquid was washed with a 5% aqueous potassium carbonate solution and water, and the organic solvent layer was dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.50 g of the desired product as a white powder (m.p. 114-117° C.).

PREPARATION EXAMPLE 4

1-(4,6-Dimethoxypyrimidin-2-yl)-2-methoxybenzimidazole (Compound Number I-18)

1-(4,6-dimethoxypyrimidin-2-yl)-2-methylsulfonylbenzimidazole (0.40 g) was dissolved in tetrahydrofuran (20 ml), and sodium methylate (0.50 g) was added thereto under cooling with ice, followed by stirring for 1 hour. Ice water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the mixture was purified by silica gel column chromatography to obtain 0.40 g of the desired product as a white powder (m.p. 121-122° C.).

PREPARATION EXAMPLE 5

1-(4,6-Dimethoxypyrimidin-2-yl)-2,5-dimethylbenzimidazole (Compound Number I-186)

In N′-(4,6-dimethoxypyrimidin-2-yl)-4-methylbenzene-1,2-diamine (2.50 g) was dissolved in acetic acid (20 ml) and acetic anhydride (10 ml), followed by reflux for 4 hours. Water was added, and the crystals were collected by filtration, washed with water and dried. Recrystallization from ethanol was carried out to obtain 1.90 g of the desired product as white feather-like crystals (m.p. 163-166° C.)

PREPARATION EXAMPLE 6

2-Amino-1-(4,6-dimethoxypyrimidin-2-yl)-5-methylbenzimidazole (Compound Number I-362)

N′-(4,6-dimethoxypyrimidin-2-yl)-4-methylbenzene-1,2-diamine (2.00 g) was dissolved in ethanol, and cyanogen bromide (1.00 g) was added thereto at room temperature, followed by stirring at 60° C. for 1 hour. Water was added, and the crystals were collected by filtration, washed with water and dried to obtain 2.03 g of the desired product as a white powder (m.p. at least 300° C.).

PREPARATION EXAMPLE 7

2-Chloro-1-(4,6-dimethoxypyrimidin-2-yl)-5-methylbenzimidazole (Compound Number I-258)

2-Amino-1-(4,6-dimethoxypyrimidin-2-yl)-5-methylbenzimidazole (1.67 g) and copper(II)chloride (0.94 g) were suspended in acetonitrile (30 ml), and tert-butyl nitrite (0.90 g) was added thereto at room temperature, followed by reflux for 30 minutes. Water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 1.48 g of the desired product as white feather-like crystals (m.p. 145-148° C.).

PREPARATION EXAMPLE 8

1-(4,6-Dimethoxypyrimidin-2-yl)-5-methyl-2-trifluoromethylbenzimidazole (Compound Number I-298)

2-(4,6-dimethoxypyrimidin-2-yl)amino-5-methyltrifluoroacetic anilide (0.60 g) and para-toluenesulfonic acid (0.05 g) were dissolved in toluene (30 ml), followed by reflux for 5 hours. Water and ethyl acetate were added, and the organic layer was washed with a saturated sodium hydrogencarbonate solution and a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.56 g of the desired product as a white powder (m.p. 93-96° C.).

PREPARATION EXAMPLE 9

1-(4,6-Dichloro-[1,3,5]triazin-2-yl)-2-methylbenzimidazole (Compound Number I-1066)

2-Methylbenzimidazole (5.0 g) was dissolved in tetrahydrofuran (50 ml), and sodium hydride (60% purity, oily) (1.6 g) was added thereto at room temperature. After stirring for 1 hour, cyanuric chloride (7.0 g) was added at room temperature, followed by stirring for 3 hours. Ice water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 2.6 g of the desired product as a white powder (m.p. at least 300° C.).

›BEST MODE FOR CARRYING OUT THE INVENTION · 2 of 4

PREPARATION EXAMPLE 10

1-(4,6-Dimethylthio-[1,3,5]triazin-2-yl)-2-methylbenzimidazole (Compound Number I-1042)

1-(4,6-dichloro-[1,3,5]triazin-2)-2-methylbenzimidazole (0.5 g) was dissolved in methanol (10 ml), and a 15% aqueous methyl mercaptan sodium salt solution (0.25 g) was added at room temperature, followed by stirring for 1 hour. After the completion of the reaction, the reaction liquid was poured into ice water, and the crystals thus deposited were collected by filtration, washed with water and dried to obtain 0.46 g of the desired product as a white powder (m.p. 176-179° C.).

PREPARATION EXAMPLE 11

5-Chloro-1-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-2-methylbenzimidazole (Compound Number I-215)

4-Chloro-N′-(4,6-dimethoxy-[1,3,5]triazin-z-2-yl)benzene-1,2-diamine (0.5 g) was dissolved in acetic acid (10 ml), and acetic anhydride (10 ml) followed by reflux for 4 hours. Water was added, and the crystals were collected by filtration, washed with water and dried. Recrystallization from ethanol was carried out to obtain 0.47 g of the desired product as white feather-like crystals (m.p. 173-176° C.).

PREPARATION EXAMPLE 12

5-Chloro-1-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-2-methylbenzimidazole (Compound Number I-215)

2-Nitro-4-chloro-N-(4,6-dimethoxy-[1,3,5]triazin-2-yl)aniline (0.5 g) and iron powder (0.3 g) were dissolved in acetic acid (10 ml) and acetic anhydride (5 ml), followed by reflux for 4 hours. The reaction mixture was cooled to room temperature, followed by filtration. The filtrate was concentrated under reduced pressure, water was added to the residue, and the crystals were collected by filtration, washed with water and dried. Recrystallization from ethanol was carried out to obtain 0.39 g of the desired product as white feather-like crystals (m.p. 173-176° C.)

PREPARATION EXAMPLE 13

2-Amino-5-chloro-1-(4,6-dimethoxy-[1,3,5]triazin-2-yl)benzimidazole (Compound Number I-368)

4-Chloro-N′-(4,6-dimethoxy-[1,3,5]triazin-2-yl)benzene-1,2-diamine (1.5 g) was dissolved in ethanol (50 ml), and cyanogen bromide (0.6 g) was added thereto at room temperature, followed by stirring at 60° C. for 1 hour. Water was added, and the crystals were collected by filtration, washed with water and dried to obtain 1.2 g of the desired product as a pink powder (m.p. 293-2960° C.)

PREPARATION EXAMPLE 14

2,5-Dichloro-1-(4,6-dimethoxy-[1,3,5]triazin-2-yl)benzimidazole (Compound Number I-277)

2-Amino-5-chloro-1-(4,6-dimethoxy-[1,3,5]triazin-2-yl)benzimidazole (1.1 g) and copper(II)chloride (0.6 g) were suspended in acetonitrile (50 ml), and tert-butyl nitrite (0.5 g) was added thereto at room temperature, followed by reflux for 30 minutes. Water was added, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.5 g of the desired product as white feather-like crystals (m.p. 146-149° C.).

PREPARATION EXAMPLE 15

1-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-5-methyl-2-trifluoromethylbenzimidazole (Compound Number I-312)

2-(4,6-dimethoxy-[1,3,5]triazin-2-yl)amino-5-methyltrifluoroacetic anilide (1.0 g) and para-toluenesulfonic acid (0.05 g) were dissolved in chlorobenzene (30 ml), followed by reflux for 5 hours. Water and ethyl acetate were added, and the organic layer was washed with a saturated sodium hydrogencarbonate solution and a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.23 g of the desired product as a white powder (m.p. 137-140° C.).

Now, 1 H-NMR(CDCl 3 /TMS, δ (ppm)) data of some among examples of the compounds of the present invention, will be shown below.

Now, Preparation Examples of intermediates for the synthesis of the compounds of the present invention will be shown below.

PREPARATION EXAMPLE 16

N-(4,6-Dimethoxypyrimidin-2-yl)-4-methyl-2-nitroaniline (Compound Number 2-6)

N-formyl-4-methyl-2-nitroaniline (25.00 g) was dissolved in dimethylformamide (400 ml), and sodium hydride (60% purity, oily) (6.11 g) was added thereto at room temperature. After stirring for 10 minutes, 2-methylsulfonyl-4,6-dimethoxypyrimidine (30.28 g) was added at room temperature, followed by stirring for 3 hours. A 10% NaOH aqueous solution was added thereto, and the crystals were collected by filtration, washed with water and dried to obtain 37.50 g of the desired product as a yellow powder (m.p. 158-161° C.).

PREPARATION EXAMPLE 17

N′-(4,6-Dimethoxypyrimidin-2-yl)-4-methylbenzene-1,2-diamine (Compound Number 3-6)

N-(4,6-dimethoxypyrimidin-2-yl)-4-methyl-2-nitroaniline (37.50 g) was dissolved in ethyl acetate (600 ml), and 10% palladium carbon (3.75 g) was added thereto. Stirring was carried out at room temperature under normal pressure in an atmosphere of hydrogen for 4 hours, followed by filtration. The solvent of the filtrate was distilled off to obtain 32.70 g of the desired product as a white powder (m.p. 128-129° C.).

PREPARATION EXAMPLE 18

2-(4,6-Dimethoxypyrimidin-2-yl)amino-5-methyltrifluoroacetic Anilide (Compound Number 1-196)

N′-(4,6-dimethoxypyrimidin-2-yl)-4-methylbenzene-1,2-diamine (0.80 g) was dissolved in pyridine (10 ml), and trifluoroacetic anhydride (0.97 g) was added thereto under cooling with ice salt. After stirring for 1 hour, diluted hydrochloric acid was added thereto, followed by extraction with ethyl acetate, washing with diluted hydrochloric acid and a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 0.88 g of the desired product as a white powder (m.p. 144-147° C.)

PREPARATION EXAMPLE 19

N-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-4-methyl-2-nitroaniline (Compound Number 2-56)

N-formyl-4-methyl-2-nitroaniline (7.2 g) was dissolved in tetrahydrofuran (50 ml), and sodium hydride (60% purity, oily) (2.0 g) was added thereto at room temperature. After stirring for 10 minutes, 2-chloro-4,6-dimethoxy-[1,3,5]triazine (7.0 g) was added at room temperature, followed by stirring for 3 hours. A 10% aqueous sodium hydroxide solution was added thereto, and the crystals were collected by filtration, washed with water and dried to obtain 10.0 g of the desired product as a yellow powder (m.p. 189-191° C.).

›BEST MODE FOR CARRYING OUT THE INVENTION · 3 of 4

SYNTHESIS EXAMPLE 20

N′-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-4-methylbenzene-1,2-diamine (Compound Number 3-56)

N-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-4-methyl-2-nitroaniline (10 g) was dissolved in ethyl acetate (50 ml) and water (50 ml), and 10 g of iron power and acetic acid (2 ml) were added thereto, followed by reflux for 2 hours. Insoluble matters were removed by filtration, and the ethyl acetate layer was washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solvent was distilled off to obtain 8.8 g of the desired product as a white powder (m.p. 180-183° C.)

PREPARATION EXAMPLE 21

2-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)amino-5-methyltrifluoroacetic Anilide (Compound Number 1-210)

N′-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-4-methylbenzene-1,2-diamine (1.0 g) was dissolved in pyridine (50 ml), and trifluoroacetic anhydride (0.8 g) was added thereto under cooling with ice salt. After stirring for 1 hour, diluted hydrochloric acid was added thereto, followed by extraction with ethyl acetate, washing with diluted hydrochloric acid and a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography to obtain 1.3 g of the desired product as a white powder (m.p. 195-198° C.).

PREPARATION EXAMPLE 22

4-Chloro-N-(4,6-dimethoxy-[1,3,5]triazin-2-yl)-2-nitroaniline (Compound Number 2-53)

4-Chloro-2-nitroaniline (5.0 g) and sodium hydrogencarbonate (3.6 g) were dissolved in tetrahydrofuran (50 ml), and cyanuric chloride (8.0 g) was added thereto, followed by stirring for 8 hours. To the reaction solution, 28% sodium methylate (11.2 g) was added, followed by ref lux for 1 hour. Water was added thereto, followed by extraction with ethyl acetate, washing with a saturated sodium chloride aqueous solution and drying over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was subjected to recrystallization from ethanol to obtain 6.3 of the desired product as a yellow powder (m.p. 206-208° C.).

The agricultural/horticultural fungicides of the present invention contain triazinylbenzimidazole derivatives represented by the general formula [I] as the active ingredients. When the compounds of the present invention are used for agricultural/horticultural fungicides, the active ingredient can be used in appropriate formulations depending on the purpose. The active ingredient is usually diluted with an inert liquid or solid carrier and is used in an appropriate dosage form such as a dust, a wettable powder, an emulsifiable concentrate or a granule by blending it with a surfactant and other ingredients, depending on its use.

Preferable examples of carriers include solid carriers such as talc, bentonite, clay, kaolin, diatomaceous earth, white carbon, vermiculite, slaked lime, silica sand, ammonium sulfate and urea and liquid carriers such as isopropyl alcohol, xylene, cyclohexanone and methylnaphthalene. Examples of surfactants and dispersants include dinaphthylmethanesulfonates, alcohol-sulfuric acid ester salts, alkylarylsulfonates, lignin sulfonate, polyoxyethylene glycol ether, polyoxyethylene oalkyl aryl ethers and polyoxyethylene sorbitan monoalkylate. Examples of adjuvants include carboxymethyl cellulose and the like. These formulations are applied after diluted to appropriate concentrations or directly.

The agricultural/horticultural fungicides of the present invention can be used for foliage treatment, soil treatment or submerged treatment. The blending proportion of the active ingredient is suitably selected depending on the case. However, the preferable proportion is from 0.1 to 20% (by weight) in the cases of a dust or a granule, and from 5 to 80% (by weight) in the cases of an emulsifiable concentrate or a wettable powder.

The dose of the agricultural/horticultural fungicides of the present invention depends on the type of the compound to be used, the disease to be controlled, the tendency of disease development, the degrees of the damage, the environmental conditions and the type of the formulation to be used. For example, for direct use as a dust or a granule, the dose of the active ingredient is selected suitably within a range of from 0.1 g to 5 kg, preferably from 1 g to 1 kg, per 10 are. For use in a liquid state as an emulsifiable concentrate or a wettable powder, the dose is selected suitably within a range of from 0.1 ppm to 10,000 ppm, preferably from 1 to 3,000 ppm.

The compounds of the present invention in the above formulations can control plant diseases caused by Oomycetes, Ascomycetes, Deuteromycetes and Basidiomycetes. Specific but non-restrictive examples of microorganisms are given below. Pseudoperonospora genus such as Pseudoperonospora cubensis , Erysiphe genus such as Erysiphe graminis , Venturia genus such as Venturia inaequalis , Pyricularia genus such as Pyricularia oryzae , Botrytis genus such as Botrytis cinerea , Rhizoctonia genus such as Rhizoctonia solani and Puccinia genus such as Puccinia recondita.

The compounds of the present invention can be used in combination with insecticides, other fungicides, herbicides, plant growth regulators or fertilizers, as the case requires. Now, typical formulations of the agricultural/horticultural fungicides of the present invention will be described with reference to Formulation Examples. Hereinafter, “%” means “% by weight”.

FORMULATION EXAMPLE 1

Dust

2% of Compound (I-45), 5% of diatomaceous earth and 93% of clay were uniformly mixed and pulverized to give a dust.

FORMULATION EXAMPLE 2

Wettable Powder

50% of Compound (I-170), 45% of diatomaceous earth, 2% of sodium dinaphthylmethanedisulfonate and 3% of sodium lignin sulfonate were uniformly mixed and pulverized to give a wettable powder.

FORMULATION EXAMPLE 3

Emulsifiable Concentrate

30% of Compound (I-309), 20% of cyclohexanone, 11% of polyoxyethylene alkyl aryl ether, 4% of calcium alkylbenzenesulfonate and 35% of methylnaphthalene were uniformly dissolved to give an emulsifiable concentrate.

›BEST MODE FOR CARRYING OUT THE INVENTION · 4 of 4

FORMULATION EXAMPLE 4

Granule

5% of Compound (I-121), 2% of the sodium salt of the lauryl alcohol sulfuric ester, 5% of sodium lignin sulfonate, 2% of carboxymethyl cellulose and 86% of clay were uniformly mixed and pulverized. The resulting mixture was kneaded with 20% of water, granulated to 14 to 32 mesh by means of an extrusion granulator and dried to give a granule.

Now, the effects of the agricultural/horticultural fungicides of the present invention will be described with reference to specific Test Example.

TEST EXAMPLE 1

›Test for Preventive Effect on Wheat Powdery Mildew

9 Wheat seeds (variety: Norin-61-go) were sown in each 9 cm×9 cm polyvinyl chloride pot, grown in a greenhouse for 8 days, then treated with 10 ml per pot of aqueous solutions of wettable powders prepared in accordance with Formulation Example 2, at a concentration of 500 ppm in terms of the active ingredients and dried in the air. Then, the seedlings were inoculated with Erysiphe graminis spores by sprinkle over the plant and placed in a greenhouse of from 20 to 25° C. 10 days after the inoculation, the total diseases area of the first leaves in each pot was observed and evaluated on the basis of the standards shown in Table 67. The results are shown in Tables 68 and 69.

The agricultural/horticultural fungicides of the present invention have a broad disease control spectrum, and have an excellent effect particularly on wheat powdery mildew. Further, they have high controlling effects on cucumber downy mildew, apple scab, rice blast, cucumber gray mold, rice sheath blight and wheat brown leaf rust, and are excellent in residual effectiveness and rain-fastness without damaging crops, and thus they are useful as agricultural/horticultural fungicides.

›Tables in the description — 69
TABLE 1 — m.p.: Melting point RI: Refractive index
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
I-1HHCHOMeOMe167-169
I-2ClHCHOMeOMe90-91
I-3BrHCHOMeOMe87-90
I-4SMeHCHOMeOMe135-137
I-5SO 2 MeHCHOMeOMe114-117
I-6MeHCHOMeOMe132-134
I-7EtHCHOMeOMe102-104
I-8PrHCHOMeOMe107-110
I-9Pr-iHCHOMeOMe70-73
I-10Pr-cHCHOMeOMe62-64
I-11BuHCHOMeOMe
I-12BnHCHOMeOMe94-96
I-13Bn(4-Cl)HCHOMeOMe122-125
I-14Bn(4-Me)HCHOMeOMe88-90
I-15Bn(4-OMe)HCHOMeOMe
I-16CH═CH 2HCHOMeOMe
I-17C≡CHHCHOMeOMe
I-18OMeHCHOMeOMe121-122
I-19OCH 2 CH═CH 2HCHOMeOMe
I-20OCH 2 C≡CHHCHOMeOMe
I-21OCH 2 CF 3HCHOMeOMe
I-22CH 2 OEtHCHOMeOMe103-104
I-23CH 2 ClHCHOMeOMe132-135
I-24CH 2 IHCHOMeOMe138-141
I-25CCl 3HCHOMeOMe128-131
I-26CF 3HCHOMeOMe79-80
I-27C 2 F 5HCHOMeOMe97-100
I-28NH 2HCHOMeOMe
TABLE 2 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-29NHMeHCHOMeOMe135-138
I-30N(Me) 2HCHOMeOMe1.5642
I-31NHPhHCHOMeOMe
I-32CO 2 EtHCHOMeOMe
I-33COMeHCHOMeOMe
I-34PhHCHOMeOMe1.6219
I-35Ph(4-Cl)HCHOMeOMe141-144
I-36Ph(4-Me)HCHOMeOMe
I-37Ph(4-OMe)HCHOMeOMe
I-38CNHCHOMeOMe167-168
I-39NO 2HCHOMeOMe
I-40HHNOMeOMe148-151
I-41ClHNOMeOMe168-171
I-42BrHNOMeOMe
I-43SMeHNOMeOMe
I-44SO 2 MeHNOMeOMe
I-45MeHNOMeOMe180-182
I-46EtHNOMeOMe
I-47PrHNOMeOMe127-128
I-48Pr-iHNOMeOMe135-141
I-49Pr-cHNOMeOMe
I-50BuHNOMeOMe
I-51BnHNOMeOMe
I-52Bn(4-Cl)HNOMeOMe
I-53Bn(4-Me)HNOMeOMe
I-54Bn(4-OMe)HNOMeOMe
I-55CH═CH 2HNOMeOMe
I-56C≡CHHNOMeOMe
I-57OMeHNOMeOMe
I-58OCH 2 CH═CH 2HNOMeOMe
I-59OCH 2 C≡CHHNOMeOMe
I-60OCH 2 CF 3HNOMeOMe
I-61OPhHNOMeOMe
I-62CH 2 OEtHNOMeOMe
TABLE 3 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-63CH 2 ClHNOMeOMe
I-64CH 2 IHNOMeOMe
I-65CCl 3HNOMeOMe
I-66CF 3HNOMeOMe143-
146
I-67C 2 F 5HNOMeOMe
I-68NH 2HNOMeOMe261-
264
I-69NHMeHNOMeOMe
I-70N(Me) 2HNOMeOMe
I-71NHPhHNOMeOMe
I-72CO 2 EtHNOMeOMe
I-73COMeHNOMeOMe
I-74PhHNOMeOMe
I-75Ph(4-Cl)HNOMeOMe
I-76Ph(4-Me)HNOMeOMe
I-77Ph(4-HNOMeOMe
OMe)
I-78CNHNOMeOMe
I-79NO 2HNOMeOMe
I-80H4-MeCHOMeOMe138-
141
I-81H4-ClCHOMeOMe
I-82H5-FCHOMeOMe175-
178
I-83H5-ClCHOMeOMe181-
184
I-84H5-BrCHOMeOMe181-
184
I-85H5-MeCHOMeOMe168-
169
I-86H5-Bu-tCHOMeOMe138-
141
I-87H5-CF 3CHOMeOMe173-
174
I-88H5-OMeCHOMeOMe162-
164
I-89H5-OEtCHOMeOMe169-
171
I-90H5-OPrCHOMeOMe
I-91H5-OCF 3CHOMeOMe138-
141
I-92H5-OCH 2 CH═CH 2CHOMeOMe
I-93H5-OCH 2 C≡CHCHOMeOMe
I-94H5-OPhCHOMeOMe
I-95H5-OPh(4-Cl)CHOMeOMe
I-96H5-OPh(4-Me)CHOMeOMe
TABLE 4 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(N D 20 )
I-97H5-OPh(4-OMe)CHOMeOMe
I-98H5-SMeCHOMeOMe
I-99H5-CH 2 OMeCHOMeOMe
I-100H5-COMeCHOMeOMe
I-101H5-COPhCHOMeOMe223-226
I-102H5-CO 2 EtCHOMeOMe185-188
I-103H5-PhCHOMeOMe162-165
I-104H5-Ph(4-Cl)CHOMeOMe
I-105H5-Ph(4-Me)CHOMeOMe
I-106H5-Ph(4-OMe)CHOMeOMe
I-107H5-NO 2CHOMeOMe
I-108H5-NH 2CHOMeOMe
I-109H5-NHMeCHOMeOMe
I-110H5-N(Me) 2CHOMeOMe
I-111H5-CNCHOMeOMe249-252
I-112H6-FCHOMeOMe192-193
I-113H6-ClCHOMeOMe199-202
I-114H6-MeCHOMeOMe134-136
I-115H6-CF 3CHOMeOMe192-193
I-116H6-OMeCHOMeOMe184-185
I-117H6-CO 2 EtCHOMeOMe184-187
I-118H6-COPhCHOMeOMe176-179
I-119H7-MeCHOMeOMe134-137
I-120H7-ClCHOMeOMe
I-121H5,6-Cl 2CHOMeOMe217-220
I-122H5,6-(Me) 2CHOMeOMe185-187
I-123H5,6-(OMe) 2CHOMeOMe
I-124H4-Br,6-CF 3CHOMeOMe188-191
I-125H4-Cl,6-CF 3CHOMeOMe204-206
I-126H4,5,6-F 3CHOMeOMe
I-127H4-MeNOMeOMe
I-128H4-ClNOMeOMe
I-129H5-FNOMeOMe
I-130H5-ClNOMeOMe175-178
TABLE 5 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-131H5-BrNOMeOMe>300
I-132H5-INOMeOMe145-148
I-133H5-MeNOMeOMe177-180
I-134H5-EtNOMeOMe120-123
I-135H5-PrNOMeOMe101-104
I-136H5-Pr-iNOMeOMe87-90
I-137H5-Bu-tNOMeOMe146-147
I-135H5-CH═CH 2NOMeOMe
I-139H5-C≡CBuNOMeOMe
I-140H5-CF 3NOMeOMe
I-141H5-OMeNOMeOMe164-167
I-142H5-OEtNOMeOMe
I-143H5-OPrNOMeOMe
I-144H5-OCF 3NOMeOMe
I-145H5-OCH 2 CH═CH 2NOMeOMe
I-146H5-OCH 2 C≡CHNOMeOMe
I-147H5-OPhNOMeOMe
I-148H5-OPh(4-Cl)NOMeOMe
I-149H5-OPh(4-Me)NOMeOMe
I-150H5-OPh(4-OMe)NOMeOMe
I-151H5-SMeNOMeOMe
I-152H5-CH 2 OMeNOMeOMe
I-153H5-COMeNOMeOMe
I-154H5-COPhNOMeOMe
I-155H5-CO 2 EtNOMeOMe
I-156H5-PhNOMeOMe
I-157H5-Ph(4-Cl)NOMeOMe
I-158H5-Ph(4-Me)NOMeOMe
I-159H5-Ph(4-OMe)NOMeOMe
I-160H5-NO 2NOMeOMe210-213
I-161H5-NH 2NOMeOMe
I-162H5-NHMeNOMeOMe
I-163H5-N(Me) 2NOMeOMe
I-164H5-CNNOMeOMe
TABLE 6 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-165H6-FNOMeOMe
I-166H6-ClNOMeOMe
I-167H6-MeNOMeOMe
I-168H6-CF 3NOMeOMe
I-169H6-OMeNOMeOMe
I-170H6-NO 2NOMeOMe>300
I-171H6-CO 2 EtNOMeOMe
I-172H6-COPhNOMeOMe
I-173H7-MeNOMeOMe
I-174H7-ClNOMeOMe
I-175H5,6-Cl 2NOMeOMe176-179
I-176H5,6-(Me) 2NOMeOMe193-196
I-177H5,6-(OMe) 2NOMeOMe
I-178H4-Br,6-CF3NOMeOMe
I-179H4-Cl,6-CF 3NOMeOMe
I-180H4,5,6-F 3NOMeOMe
I-181Me4-MeCHOMeOMe127-130
I-182Me4-ClCHOMeOMe
I-183Me5-FCHOMeOMe163-165
I-184Me5-ClCHOMeOMe153-156
I-185Me5-BrCHOMeOMe180-183
I-186Me5-MeCHOMeOMe163-166
I-187Me5-Bu-tCHOMeOMe126-129
I-188Me5-CF 3CHOMeOMe129-132
I-189Me5-OMeCHOMeOMe190-193
I-190Me5-OEtCHOMeOMe211-214
I-191Me5-OPrCHOMeOMe
I-192Me5-OCF 3CHOMeOMe137-139
I-193Me5-OPhCHOMeOMe
I-194Me5-CO 2 EtCHOMeOMe173-176
I-195Me5-COPhCHOMeOMe169-171
I-196Me5-PhCHOMeOMe164-166
I-197Me5-NH 2CHOMeOMe
I-198Me5-N(Me) 2CHOMeOMe
TABLE 7 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-199Me5-CNCHOMeOMe211-214
I-200Me6-FCHOMeOMe162-163
I-201Me6-ClCHOMeOMe165-166
I-202Me6-MeCHOMeOMe128-131
I-203Me6-CF 3CHOMeOMe162-165
I-204Me6-OMeCHOMeOMe158-161
I-205Me6-OEtCHOMeOMe
I-206Me6-OPrCHOMeOMe
I-207Me6-CO 2 EtCHOMeOMe184-187
I-208Me6-COPhCHOMeOMe179-182
I-209Me5,6-Cl 2CHOMeOMe204-206
I-210Me5,6-(Me) 2CHOMeOMe169-172
I-211Me5,6-(OMe) 2CHOMeOMe
I-212Me4-MeNOMeOMe180-182
I-213Me4-ClNOMeOMe
I-214Me5-FNOMeOMe185-188
I-215Me5-ClNOMeOMe173-176
I-216Me5-BrNOMeOMe>300
I-217Me5-INOMeOMe161-164
I-218Me5-MeNOMeOMe192-195
I-219Me5-EtNOMeOMe113-116
I-220Me5-PrNOMeOMe128-131
I-221Me5-Pr-iNOMeOMe124-125
I-222Me5-Bu-tNOMeOMe143-144
I-223Me5-CH═CH 2NOMeOMe
I-224Me5-C≡CBuNOMeOMe111-114
I-225Me5-CF 3NOMeOMe167-170
I-226Me5-OMeNOMeOMe161-164
1-227Me5-OEtNOMeOMe
I 228Me5-OPrNOMeOMe
I-229Me5-OCF 3NOMeOMe128-131
I-230Me5-OPhNOMeOMe
I-231Me5-SMeNOMeOMe
I-232Me5-CO 2 MeNOMeOMe148-151
TABLE 8 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-233Me5-CO 2 EtNOMeOMe
I-234Me5-COMeNOMeOMe155-158
I-235Me5-COPhNOMeOMe163-166
I-236Me5-PhNOMeOMe
I-237Me5-NH 2NOMeOMe
I-238Me5-N(Me) 2NOMeOMe
I-239Me5-CNNOMeOMe188-191
I-240Me6-FNOMeOMe
I-241Me6-ClNOMeOMe
I-242Me6-MeNOMeOMe130-133
I-243Me6-CF 3NOMeOMe
I-244Me6-OMeNOMeOMe
I-245Me6-OEtNOMeOMe
I-246Me6-OPrNOMeOMe
I-247Me6-CO 2 EtNOMeOMe
I-248Me6-COPhNOMeOMe
I-249Me5,6-Cl 2NOMeOMe
I-250Me4,6-(Me) 2NOMeOMe172-175
I-251Me5,6-(Me) 2NOMeOMe165-168
I-252Me5,6-(OMe) 2NOMeOMe
I-253Cl4-MeCHOMeOMe
I-254Cl4-ClCHOMeOMe
I-255Cl5-FCHOMeOMe139-142
I-256Cl5-ClCHOMeOMe159-161
I-257Cl5-BrCHOMeOMe
I-258Cl5-MeCHOMeOMe145-148
I-259Cl5-CF 3CHOMeOMe136-139
I-260Cl5-OMeCHOMeOMe148-150
I-261Cl5-OEtCHOMeOMe187-190
I-262Cl5-OPrCHOMeOMe
I-263Cl5-OCF 3CHOMeOMe102-105
I-264Cl5-OPhCHOMeOMe
I-265Cl5-COPhCHOMeOMe
I-266Cl5-PhCHOMeOMe
TABLE 9 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-267Cl5-NH 2CHOMeOMe
I-268Cl5-N(Me) 2CHOMeOMe
I-269Cl5-CNCHOMeOMe
I-270Cl6-FCHOMeOMe
I-271Cl6-ClCHOMeOMe163-164
I-272Cl6-MeCHOMeOMe98-101
I-273Cl5,6-(OMe) 2CHOMeOMe
I-274Cl4-MeNOMeOMe
I-275Cl4-ClNOMeOMe
I-276Cl5-FNOMeOMe
I-277Cl5-ClNOMeOMe146-149
I-278Cl5-BrNOMeOMe
I-279Cl5-MeNOMeOMe159-162
I-280Cl5-CF 3NOMeOMe
I-281Cl5-OMeNOMeOMe
I-282Cl5-OEtNOMeOMe
I-283Cl5-OPrNOMeOMe
I-284Cl5-OCF 3NOMeOMe
I-285Cl5-OPhNOMeOMe
I-286Cl5-COPhNOMeOMe
I-287Cl5-PhNOMeOMe
I-288Cl5-NH 2NOMeOMe
I-289Cl5-N(Me) 2NOMeOMe
I-290Cl5-CNNOMeOMe
I-291Cl6-FNOMeOMe
I-292Cl6-ClNOMeOMe
I-293Cl6-MeNOMeOMe
I-294Cl5,6-(OMe) 2NOMeOMe
I-295CF 35-FCHOMeOMe133-136
I-296CF 35-ClCHOMeOMe114-116
I-297CF 35-BrCHOMeOMe
I-298CF 35-MeCHOMeOMe93-96
I-299CF 35-CF 3CHOMeOMe78-79
I-300CF 35-OMeCHOMeOMe129-132
TABLE 10 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-301CF 35-OEtCHOMeOMe151-154
I-302CF 35-OPrCHOMeOMe
I-303CF 35-N(Me) 2CHOMeOMe
I-304CF 35-CNCHOMeOMe
I-305CF 36-FCHOMeOMe
I-306CF 36-ClCHOMeOMe
I-307CF 36-MeCHOMeOMe132-135
I-308CF 35,6-(OMe) 2CHOMeOMe
I-309CF 35-FNOMeOMe170-173
I-310CF 35-ClNOMeOMe135-138
I-311CF 35-BrNOMeOMe111-114
I-312CF 35-MeNOMeOMe137-140
I-313CF 35-EtNOMeOMe104-107
I-314CF 35-PrNOMeOMe89-92
I-315CF 35-Pr-iNOMeOMe118-121
I-316CF 35-Bu-tNOMeOMe113-116
I-317CF 35-CF 3NOMeOMe
I-318CF 35-OMeNOMeOMe165-168
I-319CF 35-OEtNOMeOMe
I-32OCF 35-OPrNOMeOMe
I-321CF 35-OCF 3NOMeOMe187-190
I-322CF 35-SMeNOMeOMe
I-323CF 35-NHMeNOMeOMe
I-324CF 35-N(Me) 2NOMeOMe
I-325CF 35-CNNOMeOMe188-191
I-326CF 35-CO 2 MeNOMeOMe126-129
I-327CF 35-INOMeOMe115-118
I-328CF 36-FNOMeOMe
I-329CF 36-ClNOMeOMe
I-330CF 36-MeNOMeOMe
I-331CF 35,6-(OMe) 2NOMeOMe
I-332Et5-FCHOMeOMe135-138
I-333Et5-ClCHOMeOMe137-140
I-334Et5-MeCHOMeOMe120-122
TABLE 11 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-335Et5-CF 3CHOMeOMe117-118
I-336Et5-OMeCHOMeOMe118-120
I-337Et5-OEtCHOMeOMe
I-338Et5-OPrCHOMeOMe
I-339Et5-N(Me) 2CHOMeOMe
I-340Et5-CNCHOMeOMe
I-341Et6-FCHOMeOMe
I-342Et6-ClCHOMeOMe
I-343Et6-MeCHOMeOMe
I-344Et5,6-(OMe) 2CHOMeOMe
I-345Et5-FNOMeOMe
I-346Et5-ClNOMeOMe125-128
I-347Et5-MeNOMeOMe
I-348Et5-CF 3NOMeOMe
I-349Et5-OMeNOMeOMe
I-350Et5-OEtNOMeOMe
I-351Et5-OPrNOMeOMe
I-352Et5-N(Me) 2NOMeOMe
I-353Et5-CNNOMeOMe
I-354Et6-FNOMeOMe
I-355Et6-ClNOMeOMe
I-356Et6-MeNOMeOMe
I-357Et5,6-(OMe) 2NOMeOMe
I-358Pr5-ClNOMeOMe128-131
I-359Pr-i5-ClNOMeOMe160-163
I-360Pr-c5-ClNOMeOMe146-149
I-361NH 25-FCHOMeOMe236-239
I-362NH 25-MeCHOMeOMe>300
I-363NH 25-CF 3CHOMeOMe268-271
I-364NH 25-OMeCHOMeOMe232-235
I-365NH 25-OEtCHOMeOMe239-242
I-366NH 26-MeCHOMeOMe>300
I-367NH 25,6-(OMe) 2CHOMeOMe
I-368NH 25-ClNOMeOMe293-296
TABLE 12 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-369NH 25-MeNOMeOMe272-275
I-370NH 25-CF 3NOMeOMe
I-371NH 25-OMeNOMeOMe
I-372NH 25-OEtNOMeOMe
I-373NH 26-MeNOMeOMe
I-374NH 25,6-(OMe) 2NOMeOMe
I-375NHMe5-ClNOMeOMe238-241
I-376N(Me) 25-ClNOMeOMe66-69
I-377CH 2 OMe5-ClNOMeOMe105-108
I-378Ph5-ClNOMeOMe137-140
I-379Bn5-ClNOMeOMe192-195
I-380CN5-ClCHOMeOMe223-226
I-381CN5-MeCHOMeOMe229-231
I-382CN5-CF 3CHOMeOMe
I-383CN5-OMeCHOMeOMe
I-384CN5-ClNOMeOMe
I-385CN5-MeNOMeOMe
I-386CN5-CF 3NOMeOMe
I-387CN5-OMeNOMeOMe
I-388SMe5-ClCHOMeOMe184-187
I-389SMe5-MeCHOMeOMe155-158
I-390SMe5-CF 3CHOMeOMe
I-391SMe5-OMeCHOMeOMe
I-392SMe6-ClCHOMeOMe
I-393SMe6-MeCHOMeOMe
I-394SMe5-ClNOMeOMe135-138
I-395SMe5-MeNOMeOMe
I-396SMe5-CF 3NOMeOMe
I-397SMe5-OMeNOMeOMe
I-398SMe6-ClNOMeOMe
I-399SMe6-MeNOMeOMe
I-400CCl 35-ClCHOMeOMe132-134
I-401CCl 35-MeCHOMeOMe
I-402CCl 35-OMeCHOMeOMe
TABLE 13 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-403CCl 36-ClCHOMeOMe
I-404CCl 36-MeCHOMeOMe136-139
I-405CCl 35-ClNOMeOMe123-126
I-406CCl 35-MeNOMeOMe140-151
I-407CCl 35-OMeNOMeOMe
I-408CCl 35-BrNOMeOMe
I-409CCl 36-ClNOMeOMe
I-410CCl 36-MeNOMeOMe
I-411CF 2 Cl5-MeNOMeOMe109-111
I-412CF 2 Cl5-ClNOMeOMe86-89
I-413CF 2 Cl5-BrNOMeOMe
I-414CF 2 Cl5-OMeNOMeOMe
I-415CH 2 Cl5-MeNOMeOMe143-145
I-416CH 2 Cl5-ClNOMeOMe160-161
I-417CH 2 Cl5-BrNOMeOMe
I-418CH 2 Cl5-OMeNOMeOMe
I-419C 2 F 55-MeNOMeOMe
I-420C 2 F 55-ClNOMeOMe
I-421C 2 F 55-BrNOMeOMe
I-422C 2 F 55-OMeNOMeOMe
I-423SO 2 Me5-ClCHOMeOMe149-152
I-424SO 2 Me5-MeCHOMeOMe176-177
I-425SO 2 Me6-MeCHOMeOMe
I-426SO 2 Me5-ClNOMeOMe
I-427SO 2 Me5-MeNOMeOMe
I-428SO 2 Me6-MeNOMeOMe
I-429OMe5-ClCHOMeOMe182-185
I-430OMe6-ClCHOMeOMe178-180
I-431OMe5-ClNOMeOMe
I-432OMe6-ClNOMeOMe
I-433HHNOMeOEt
I-434H5-ClNOMeOEt
I-435H5-BrNOMeOEt194-196
I-436H5-MeNOMeOEt
TABLE 14 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-437MeHNOMeOEt
I-438Me5-ClNOMeOEt153-156
I-439Me5-BrNOMeOEt143-145
I-440Me5-MeNOMeOEt155-156
I-441Cl5-ClNOMeOEt
I-442Cl5-BrNOMeOEt
I-443Cl5-MeNOMeOEt
I-444CF 3HNOMeOEt
I-445CF 35-MeNOMeOEt147-150
I-446CF 35-ClNOMeOEt149-151
I-447CF 35-BrNOMeOEt138-139
I-448CF 2 Cl5-ClNOMeOEt
I-449CF 2 Cl5-BrNOMeOEt
I-450CF 2 Cl5-MeNOMeOEt
I-451CH 2 Cl5-ClNOMeOEt
I-452CH 2 Cl5-BrNOMeOEt
I-453CH 2 Cl5-MeNOMeOEt
I-454C 2 F 55-ClNOMeOEt
I-455C 2 F 55-BrNOMeOEt
I-456C 2 F 55-MeNOMeOEt
I-457HHCHOEtOEt122-124
I-458ClHCHOEtOEt79-82
I-459BrHCHOEtOEt
I-460SMeHCHOEtOEt122-125
I-461MeHCHOEtOEt88-91
I-462EtHCHOEtOEt90-93
I-463OMeHCHOEtOEt87-89
I-464OEtHCHOEtOEt96-99
I-465CF 3HCHOEtOEt90-92
I-466NH 2HCHOEtOEt222-225
I-467CNHCHOEtOEt153-156
I-468HHNOEtOEt
I-469ClHNOEtOEt
I-470BrHNOEtOEt
TABLE 15 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-471SMeHNOEtOEt
I-472MeHNOEtOEt
I-473EtHNOEtOEt
I-474OMeHNOEtOEt
I-475OEtHNOEtOEt
I-476CF 3HNOEtOEt
I-477NH 2HNOEtOEt
I-478CNHNOEtOEt
I-479H5-FCHOEtOEt156-159
I-480H5-ClCHOEtOEt177-180
I-481H5-BrCHOEtOEt
I-482H5-MeCHOEtOEt135-138
I-483H5-CF 3CHOEtOEt165-168
I-484H5-OMeCHOEtOEt
I-485H5-OEtCHOEtOEt
I-486H6-ClCHOEtOEt164-167
I-487H5,6-(OMe) 2CHOEtOEt
I-488H5-FNOEtOEt
I-489H5-ClNOEtOEt
I-490H5-BrNOEtOEt170-173
I-491H5-MeNOEtOEt
I-492H5-Bu-tNOEtOEt107-110
I-493H5-CF 3NOEtOEt
I-494H5-OMeNOEtOEt
I-495H5-OEtNOEtOEt
I-496H6-ClNOEtOEt
I-497H5,6-(OMe) 2NOEtOEt
I-498Me5-FCHOEtOEt131-133
I-499Me5-ClCHOEtOEt171-174
I-500Me5-BrCHOEtOEt
I-501Me5-MeCHOEtOEt119-122
I-502Me5-CF 3CHOEtOEt131-134
I-503Me5-OMeCHOEtOEt141-144
I-504Me5-OEtCHOEtOEt
TABLE 16 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-505Me5-OCF 3CHOEtOEt
I-506Me5-CNCHOEtOEt
I-507Me6-FCHOEtOEt133-134
I-508Me6-ClCHOEtOEt146-149
I-509Me6-MeCHOEtOEt
I-510Me6-CF 3CHOEtOEt138-141
I-511Me6-OMeCHOEtOEt135-138
I-512Me5,6-(OMe) 2CHOEtOEt
I-513Me5-FNOEtOEt
I-514Me5-ClNOEtOEt175-178
I-515Me5-BrNOEtOEt169-172
I-516Me5-MeNOEtOEt141-144
I-517Me5-Bu-tNOEtOEt107-109
I-518Me5-CF 3NOEtOEt
I-519Me5-OMeNOEtOEt
I-520Me5-OEtNOEtOEt
I-521Me5-OCF 3NOEtOEt
I-522Me5-CNNOEtOEt
I-523Me6-FNOEtOEt
I-524Me6-ClNOEtOEt
I-525Me6-MeNOEtOEt
I-526Me6-CF 3NOEtOEt
I-527Me6-OMeNOEtOEt
I-528Me5,6-(OMe) 2NOEtOEt
I-529Cl5-ClCHOEtOEt
I-530Cl5-MeCHOEtOEt101-103
I-531Cl5-OMeCHOEtOEt153-156
I-532Cl5-OEtCHOEtOEt
I-533Cl5,6-(OMe) 2CHOEtOEt
I-534Cl5-ClNOEtOEt130-133
I-535Cl5-MeNOEtOEt
I-536Cl5-OMeNOEtOEt
I-537Cl5-OEtNOEtOEt
I-538Cl5,6-(OMe) 2NOEtOEt
TABLE 17 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-539CF 35-MeCHOEtOEt
I-540CF 35-OMeCHOEtOEt
I-541CF 35,6-(OMe) 2CHOEtOEt
I-542CF 3HNOEtOEt
I-543CF 35-MeNOEtOEt163-165
I-544CF 35-OMeNOEtOEt140-143
I-545CF 35-ClNOEtOEt138-141
I-546CF 35-BrNOEtOEt120-123
I-547Et5-MeCHOEtOEt
I-548Et5-OMeCHOEtOEt
I-549Et5,6-(OMe) 2CHOEtOEt
I-550CCl 35-ClNOEtOEt110-113
I-551CCl 35-BrNOEtOEt
I-552CCl 35-MeNOEtOEt
I-553CCl 35-OMeNOEtOEt
I-554CF 2 Cl5-ClNOEtOEt
I-555CF 2 Cl5-BrNOEtOEt
I-556CF 2 Cl5-MeNOEtOEt
I-557CH 2 Cl5-ClNOEtOEt
I-558CH 2 Cl5-BrNOEtOEt
I-559CH 2 Cl5-MeNOEtOEt
I-560C 2 F 55-ClNOEtOEt
I-561C 2 F 55-BrNOEtOEt
I-562C 2 F 55-MeNOEtOEt
I-563CN5-ClCHOEtOEt170-172
I-564CN5-OMeCHOEtOEt
I-565CN5,6-(OMe) 2CHOEtOEt
I-566CN5-MeNOEtOEt
I-567CN5-OMeNOEtOEt
I-568CN5-ClNOEtOEt
I-569SMe5-ClCHOEtOEt167-169
I-570SMe5-MeCHOEtOEt
I-571SMe5-ClNOEtOEt
I-572SMe5-MeNOEtOEt
TABLE 18 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-573SO 2 Me5-ClCHOEtOEt167-170
I-574SO 2 Me5-MeCHOEtOEt
I-575OMe5-ClCHOEtOEt143-146
I-576HHCHOPrOPr89-90
I-577HHNOPrOPr
I-578H5-ClNOPrOPr
I-579H5-BrNOPrOPr
I-580Me5-ClNOPrOPr128-131
I-581Me5-BrNOPrOPr
I-582Me5-MeNOPrOPr
I-583CF 35-ClNOPrOPr71-74
I-584CF 35-BrNOPrOPr
I-585CF 35-MeNOPrOPr
I-586HHCHOPr-iOPr-i115-117
I-587Me5-ClCHOPr-iOPr-i
I-588Me5-MeCHOPr-iOPr-i
I-589HHNOPr-iOPr-i
I-590H5-ClNOPr-iOPr-i
I-591H5-BrNOPr-iOPr-i
I-592Me5-ClNOPr-iOPr-i85-88
I-593Me5-BrNOPr-iOPr-i
I-594Me5-MeNOPr-iOPr-i
I-595CF 35-ClNOPr-iOPr-i97-100
I-596CF 35-BrNOPr-iOPr-i
I-597CF 35-MeNOPr-iOPr-i
I-598HHNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-599H5-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-600H5-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-601Me5-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2158-161
I-602Me5-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-603Me5-MeNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-604CF 35-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-605CF 35-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
I-606CF 35-MeNOCH 2 CH═CH 2OCH 2 CH═CH 2
TABLE 19 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-607HHNOCH 2 C≡CHOCH 2 C≡CH
I-608H5-ClNOCH 2 C≡CHOCH 2 C≡CH
I-609H5-BrNOCH 2 C≡CHOCH 2 C≡CH
I-610Me5-ClNOCH 2 C≡CHOCH 2 C≡CH
I-611Me5-BrNOCH 2 C≡CHOCH 2 C≡CH
I-612Me5-MeNOCH 2 C≡CHOCH 2 C≡CH
I-613CF 35-ClNOCH 2 C≡CHOCH 2 C≡CH
I-614CF 35-BrNOCH 2 C≡CHOCH 2 C≡CH
I-615CF 35-MeNOCH 2 C≡CHOCH 2 C≡CH
I-616Me5-ClCHOCH 2 CNOCH 2 CN
I-617Me5-MeCHOCH 2 CNOCH 2 CN
I-618H5-BrNOCH 2 CNOCH 2 CN
I-619Me5-ClNOCH 2 CNOCH 2 CN
I-620Me5-BrNOCH 2 CNOCH 2 CN
I-621Me5-MeNOCH 2 CNOCH 2 CN
I-622CF 35-ClNOCH 2 CNOCH 2 CN
I-623CF 35-BrNOCH 2 CNOCH 2 CN
I-624CF 35-MeNOCH 2 CNOCH 2 CN
I-625Me5-ClCHOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-626Me5-MeCHOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-627H5-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-628Me5-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-629Me5-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-630Me5-MeNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-631CF 35-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-632CF 35-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-633CF 35-MeNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
I-634H5-BrNOCH 2 Pr-cOCH 2 Pr-c
I-635Me5-ClNOCH 2 Pr-cOCH 2 Pr-c
I-636Me5-BrNOCH 2 Pr-cOCH 2 Pr-c
I-637Me5-MeNOCH 2 Pr-cOCH 2 Pr-c
I-638CF 35-ClNOCH 2 Pr-cOCH 2 Pr-c
I-639CF 35-BrNOCH 2 Pr-cOCH 2 Pr-c
I-640CF 35-MeNOCH 2 Pr-cOCH 2 Pr-c
TABLE 20 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-641Me5-MeCHOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-642Me5-ClCHOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-643Me5-MeNOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-644Me5-ClNOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-645CF 35-MeNOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-646CF 35-ClNOCH 2 CH 2 ClOCH 2 CH 2 Cl
I-647Me5-ClNOCH 2 CH 2 FOCH 2 CH 2 F
I-648Me5-MeNOCH 2 CH 2 FOCH 2 CH 2 F
I-649CF 35-MeNOCH 2 CH 2 FOCH 2 CH 2 F
I-650CF 35-ClNOCH 2 CH 2 FOCH 2 CH 2 F
I-651Me5-ClNOCH 2 CF 3OCH 2 CF 3
I-652Me5-MeNOCH 2 CF 3OCH 2 CF 3
I-653CF 35-MeNOCH 2 CF 3OCH 2 CF 3
I-654CF 35-ClNOCH 2 CF 3OCH 2 CF 3
I-655HHCHOBnOBn
I-656HHNOBnOBn
I-657HHNOBn(4-Cl)OBn(4-Cl)
I-658HHNOBn(4-Me)OBn(4-Me)
I-659HHNOBn(4-OBn(4-
OMe)OMe)
I-660HHCHOMeOPh131-132
I-661HHNOMeOPh
I-662HHNOMeOPh(4-Cl)
I-663HHNOMeOPh(4-Me)
I-664HHNOMeOPh(4-OMe)
I-665HHCHOMeOCHF 2138-139
I-666HHNOMeOCHF 2
I-667HHCHOMeH114-116
I-668MeHCHOMeH
I-669H5-ClCHOMeH173-176
I-670H5-MeCHOMeH140-142
I-671Me5-ClCHOMeH127-130
I-672Me5-MeCHOMeH113-114
I-673Me5-CF 3CHOMeH
I-674Me5-OMeCHOMeH
TABLE 21 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-675Me6-ClCHOMeH126-130
I-676Me5,6-(OMe) 2CHOMeH
I-677Cl5-ClCHOMeH
I-678Cl5-MeCHOMeH
I-679Cl5-CF 3CHOMeH
I-680Cl5-OMeCHOMeH
I-681Cl5,6-(OMe) 2CHOMeH
I-682CF 35-ClCHOMeH107-108
I-683CF 35-MeCHOMeH76-79
I-684CF 35-CF 3CHOMeH
I-685CF 35-OMeCHOMeH
I-686Et5-ClCHOMeH
I-687Et5-MeCHOMeH
I-688Et5-CF 3CHOMeH
I-689Et5-OMeCHOMeH
I-690HHCHOEtH104-107
I-691MeHCHOEtH
I-692H5-ClCHOEtH158-160
I-693H5-MeCHOEtH131-132
I-694Me5-ClCHOEtH153-155
I-695Me5-MeCHOEtH109-111
I-696Me5-CF 3CHOEtH
I-697Me5-OMeCHOEtH
I-698Me5,6-(OMe) 2CHOEtH
I-699Me6-ClCHOEtH117-118
I-700Cl5-MeCHOEtH
I-701Cl5-CF 3CHOEtH
I-702Cl5-OMeCHOEtH
I-703Cl5,6-(OMe) 2CHOEtH
I-704CF 35-ClCHOEtH125-128
I-705CF 35-MeCHOEtH86-87
I-706CF 35-OMeCHOEtH
I-707Et5-ClCHOEtH
I-708Et5-MeCHOEtH
TABLE 22 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-709Et5-CF 3CHOEtH
I-710Et5-OMeCHOEtH
I-711HHCHOPrH88-
86
I-712Me5-MeCHOPrH
I-713Me5-ClCHOPrH
I-714Me5-OMeCHOPrH
I-715HHCHOCH 2 CH═CH 2H
I-716Me5-MeCHOCH 2 CH═CH 2H
I-717Me5-ClCHOCH 2 CH═CH 2H
I-718Me5-OMeCHOCH 2 CH═CH 2H
I-719HHCHOBnH
I-720Me5-MeCHOBnH
I-721Me5-ClCHOBnH
I-722HHCHOPhH257-
260
I-723HHCHOPh(4-Cl)H
I-724HHCHOPh(4-Me)H
I-725HHCHOPh(4-OMe)H
I-726HHCHOMeMe107-
110
I-727MeHCHOMeMe
I-728H5-ClCHOMeMe
I-729H5-MeCHOMeMe
I-730H5-CF 3CHOMeMe
I-731Me5-ClCHOMeMe124-
127
I-732Me5-MeCHOMeMe
I-733Me5-CF 3CHOMeMe
I-734Me5-OMeCHOMeMe
I-735Me6-ClCHOMeMe
I-736Me5,6-(OMe) 2CHOMeMe
I-737Cl5-ClCHOMeMe
I-738Cl5-MeCHOMeMe
I-739Cl5-OMeCHOMeMe
I-740Cl5,6-(OMe) 2CHOMeMe
I-741CF 35-ClCHOMeMe
I-742CF 35-MeCHOMeMe
TABLE 23 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-743CF 35-OMeCHOMeMe
I-744Et5-ClCHOMeMe
I-745Et5-MeCHOMeMe
I-746Et5-OMeCHOMeMe
I-747HHNOMeMe
I-748H5-ClNOMeMe
I-749H5-MeNOMeMe
I-750H5-CF 3NOMeMe
I-751Me5-ClNOMeMe
I-752Me5-MeNOMeMe124-127
I-753Me5-CF 3NOMeMe
I-754Me5-OMeNOMeMe
I-755Me6-ClNOMeMe
I-756Me5,6-(OMe) 2NOMeMe
I-757Cl5-ClNOMeMe
I-758Cl5-MeNOMeMe117-120
I-759Cl5-OMeNOMeMe
I-760Cl5,6-(OMe) 2NOMeMe
I-761CF 35-ClNOMeMe
I-762CF 35-MeNOMeMe117-120
I-763CF 35-OMeNOMeMe
I-764Et5-ClNOMeMe
I-765Et5-MeNOMeMe
I-766Et5-OMeNOMeMe
I-767NH 25-MeNOMeMe>300
I-768HHCHOEtMe57-60
I-769MeHCHOEtMe92-94
I-770CF 3HCHOEtMe
I-771ClHCHOEtMe95-96
I-772H5-MeCHOEtMe105-108
I-773Me5-FCHOEtMe
I-774Me5-ClCHOEtMe
I-775Me5-MeCHOEtMe108-110
I-776Me5-CF 3CHOEtMe
TABLE 24 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-777Me5-OMeCHOEtMe
I-778Me5-CNCHOEtMe
I-779Me6-ClCHOEtMe
I-780Me5,6-(OMe) 2CHOEtMe
I-781Cl5-ClCHOEtMe
I-782Cl5-MeCHOEtMe
I-783Cl5-CF 3CHOEtMe
I-784Cl5-OMeCHOEtMe
I-785Cl5,6-(OMe) 2CHOEtMe
I-786CF 35-ClCHOEtMe
I-787CF 35-MeCHOEtMe117-118
I-788CF 35-OMeCHOEtMe
I-789Et5-ClCHOEtMe
I-790Et5-MeCHOEtMe
I-791Et5-CF 3CHOEtMe
I-792Et5-OMeCHOEtMe
I-793HHNOEtMe
I-794H5-BrNOEtMe
I-795Me5-ClNOEtMe
I-796Me5-BrNOEtMe
I-797Me5-MeNOEtMe
I-798Me5-CF 3NOEtMe
I-799Cl5-ClNOEtMe
I-800Cl5-MeNOEtMe
I-801CF 35-ClNOEtMe
I-802CF 35-BrNOEtMe
I-803CF 35-MeNOEtMe
I-804HHCHOPrMe47-50
I-805H5-OMeCHOPrMe100-102
I-806MeHCHOPrMe75-78
I-807CF 3HCHOPrMe
I-808H5-ClCHOPrMe
I-809H5-MeCHOPrMe73-76
I-810Me5-FCHOPrMe
TABLE 25 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-811Me5-ClCHOPrMe90-93
I-812Me5-MeCHOPrMe59-62
I-813Me5-OMeCHOPrMe99-101
I-814Me6-ClCHOPrMe109-112
I-815Me5,6-(OMe) 2CHOPrMe
I-816Cl5-ClCHOPrMe
I-817Cl5-MeCHOPrMe76-77
I-818Cl5-OMeCHOPrMe87-90
I-819Cl5,6-(OMe) 2CHOPrMe
I-820CF 35-ClCHOPrMe
I-821CF 35-MeCHOPrMe
I-822CF 35-CF 3CHOPrMe
I-823CF 35-OMeCHOPrMe
I-824Et5-ClCHOPrMe
I-825Et5-MeCHOPrMe
I-826Et5-OMeCHOPrMe
I-827HHNOPrMe
I-828H5-BrNOPrMe
I-829Me5-ClNOPrMe
I-830Me5-BrNOPrMe
I-831Me5-MeNOPrMe104-107
I-832Me5-CF 3NOPrMe
I-833Cl5-ClNOPrMe
I-834Cl5-MeNOPrMe
I-835CF 35-ClNOPrMe
I-836CF 35-BrNOPrMe
I-837CF 35-MeNOPrMe
I-838NH 25-MeNOPrMe152-153
I-839HHCHOPr-iMe66-68
I-840MeHCHOPr-iMe1.5805
I-841CF 3HCHOPr-iMe
I-842H5-ClCHOPr-iMe
I-843H5-MeCHOPr-iMe
I-844Me5-FCHOPr-iMe
TABLE 26 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-845Me5-ClCHOPr-iMe
I-846Me5-MeCHOPr-iMe
I-847Me5-OMeCHOPr-iMe
I-848Me6-ClCHOPr-iMe
I-849Me5,6-(OMe) 2CHOPr-iMe
I-850Cl5-ClCHOPr-iMe
I-851Cl5-MeCHOPr-iMe
I-852Cl5-CF 3CHOPr-iMe
I-853Cl5-OMeCHOPr-iMe
I-854Cl5,6-(OMe) 2CHOPr-iMe
I-855CF 35-ClCHOPr-iMe
I-856CF 35-MeCHOPr-iMe
I-857CF 35-OMeCHOPr-iMe
I-858Et5-ClCHOPr-iMe
I-859Et5-MeCHOPr-iMe
I-860Et5-OMeCHOPr-iMe
I-861HHNOPr-iMe
I-862H5-BrNOPr-iMe
I-863Me5-ClNOPr-iMe
I-864Me5-BrNOPr-iMe
I-865Me5-MeNOPr-iMe
I-866Me5-CF 3NOPr-iMe
I-867Cl5-ClNOPr-iMe
I-868Cl5-MeNOPr-iMe
I-869CF 35-ClNOPr-iMe
I-870CF 35-BrNOPr-iMe
I-871CF 35-MeNOPr-iMe
I-872HHCHOBuMe1.5795
I-873MeHCHOBuMe73-76
I-874Me5-ClCHOBuMe
I-875Me5-MeCHOBuMe
I-876Me5-OMeCHOBuMe
I-877Cl5-ClCHOBuMe
I-878Cl5-MeCHOBuMe
TABLE 27 — m.p. (° C.)
Com-or
poundRI
No.XYnAR 1R 2(n D 20 )
I-879Cl5-OMeCHOBuMe
I-880CF 35-ClCHOBuMe
I-881CF 35-MeCHOBuMe
I-882CF 35-OMeCHOBuMe
I-883HHCHOCH 2 CH═CH 2Me55-58
I-884H5-MeCHOCH 2 CH═CH 2Me
I-885MeHCHOCH 2 CH═CH 2Me84-87
I-886Me5-ClCHOCH 2 CH═CH 2Me
I-887Me5-MeCHOCH 2 CH═CH 2Me
I-888Me5-OMeCHOCH 2 CH═CH 2Me
I-889Cl5-ClCHOCH 2 CH═CH 2Me
I-890Cl5-MeCHOCH 2 CH═CH 2Me
I-891CF 35-ClCHOCH 2 CH═CH 2Me
I-892CF 35-MeCHOCH 2 CH═CH 2Me
I-893CF 35-OMeCHOCH 2 CH═CH 2Me
I-894HHCHOCH 2 C≡CHMe145-148
I-895H5-MeCHOCH 2 C≡CHMe183-186
I-896MeHCHOCH 2 C≡CHMe147-149
I-897Me5-ClCHOCH 2 C≡CHMe
I-898Me5-MeCHOCH 2 C≡CHMe147-150
I-899Me5-OMeCHOCH 2 C≡CHMe
I-900Cl5-ClCHOCH 2 C≡CHMe
I-901Cl5-MeCHOCH 2 C≡CHMe
I-902CF 35-ClCHOCH 2 C≡CHMe
I-903CF 35-MeCHOCH 2 C≡CHMe113-116
I-904NH 25-MeCHOCH 2 C≡CHMe225-228
I-905HHCHOBnMe
I-906HHCHOPn-cMe1.5965
I-907MeHCHOPn-cMe1.5941
I-908Me5-ClCHOPn-cMe
I-909Me5-ClNOPn-cMe
I-910HHCHSMeMe
I-911MeHCHSMeMe139-142
I-912Me5-MeCHSMeMe
TABLE 28 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-913Me5-ClCHSMeMe
I-914HHNSMeMe
I-915Me5-MeNSMeMe134-137
I-916Me5-ClNSMeMe
I-917HHCHOMeEt
I-918Me5-MeCHOMeEt
I-919Me5-ClCHOMeEt
I-920Me5-CF 3CHOMeEt
I-921Me5-OMeCHOMeEt
I-922Cl5-MeCHOMeEt
I-923Cl5-ClCHOMeEt
I-924HHCHOEtEt
I-925Me5-MeCHOEtEt
I-926Me5-ClCHOEtEt
I-927Me5-CF 3CHOEtEt
I-928Me5-OMeCHOEtEt
I-929Cl5-MeCHOEtEt
I-930Cl5-ClCHOEtEt
I-931HHCHOPrEt
I-932Me5-MeCHOPrEt
I-933Me5-ClCHOPrEt
I-934Me5-CF 3CHOPrEt
I-935Me5-OMeCHOPrEt
I-936Cl5-MeCHOPrEt
I-937Cl5-ClCHOPrEt
I-938HHNOMeEt
I-939H5-BrNOMeEt125-128
I-940Me5-MeNOMeEt
I-941Me5-ClNOMeEt134-137
I-942Me5-BrNOMeEt134-141
I-943Cl5-MeNOMeEt
I-944Cl5-ClNOMeEt
I-945CF 35-MeNOMeEt86-89
I-946CF 35-ClNOMeEt79-82
TABLE 29 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-947CF 35-BrNOMeEt97-100
I-948HHNOEtEt
I-949H5-BrNOEtEt79-82
I-950Me5-MeNOEtEt
I-951Me5-ClNOEtEt
I-952Me5-BrNOEtEt96-98
I-953Cl5-MeNOEtEt
I-954Cl5-ClNOEtEt
I-955CF 35-MeNOEtEt
I-956CF 35-ClNOEtEt66-67
I-957CF 35-BrNOEtEt97-100
I-958HHCHOMePr78-80
I-959MeHCHOMePr1.5892
I-960ClHCHOMePr1.6009
I-961H5-ClCHOMePr
I-962H5-MeCHOMePr116-119
I-963Me5-FCHOMePr
I-964Me5-ClCHOMePr113-116
I-965Me5-MeCHOMePr105-107
I-966Me5-OMeCHOMePr
I-967Me6-ClCHOMePr68-71
I-968Cl5-ClCHOMePr
I-969Cl5-MeCHOMePr
I-970Cl5-OMeCHOMePr
I-971CF 35-ClCHOMePr
I-972CF 35-MeCHOMePr
I-973CF 35-OMeCHOMePr
I-974HHCHOEtPr
I-975H5-ClCHOEtPr
I-976H5-MeCHOEtPr
I-977Me5-FCHOEtPr
I-978Me5-ClCHOEtPr
I-979Me5-MeCHOEtPr
I-980Me5-CF 3CHOEtPr
TABLE 30 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-981Me5-OMeCHOEtPr
I-982Cl5-ClCHOEtPr
I-983Cl5-MeCHOEtPr
I-984Cl5-CF 3CHOEtPr
I-985Cl5-OMeCHOBtPr
I-986CF 35-ClCHOEtPr
I-987CF 35-MeCHOEtPr
I-988CF 35-OMeCHOEtPr
I-989HHCHOPrPr
I-990Me5-MeCHOPrPr
I-991Me5-ClCHOPrPr
I-992Me5-OMeCHOPrPr
I-993Cl5-MeCHOPrPr
I-994Cl5-ClCHOPrPr
I-995HHNOMePr
I-996H5-BrNOMePr
I-997Me5-ClNOMePr
I-998Me5-BrNOMePr
I-999Me5-MeNOMePr112-115
I-1000Cl5-ClNOMePr
I-1001Cl5-MeNOMePr
I-1002CF 35-ClNOMePr
I-1003CF 35-BrNOMePr
I-1004CF 35-MeNOMePr92-95
I-1005HHNOEtPr
I-1006H5-BrNOEtPr
I-1107Me5-ClNOEtPr
I-1008Me5-BrNOEtPr
I-1009Me5-MeNOEtPr
I-1010Cl5-ClNOEtPr
I-1011Cl5-MeNOPrPr
I-1012CF 35-ClNOPrPr
I-1013CF 35-BrNOPrPr
I-1014CF 35-MeNOPrPr
TABLE 31 — m.p. (° C.) or
CompoundRI
No.XYnAR 1R 2(n D 20 )
I-1015HHNOMePr-c
I-1016H5-BrNOMePr-c154-157
I-1017Me5-ClNOMePr-c116-119
I-1018Me5-BrNOMePr-c121-124
I-1019Me5-MeNOMePr-c167-170
I-1020CF 35-ClNOMePr-c101-104
I-1021CF 35-BrNOMePr-c119-122
I-1022CF 35-MeNOMePr-c116-119
I-1023HHNOEtPr-c
I-1024H5-BrNOEtPr-c137-140
I-1025Me5-ClNOEtPr-c130-133
I-1026Me5-BrNOEtPr-c124-127
I-1027Me5-MeNOEtPr-c131-133
I-1028CF 35-ClNOEtPr-c82-85
I-1029CF 35-BrNOEtPr-c105-108
I-1030CF 35-MeNOEtPr-c79-82
I-1031HHNSMePr-c
I-1032H5-BrNSMePr-c
I-1033Me5-ClNSMePr-c
I-1034Me5-BrNSMePr-c
I-1035Me5-MeNSMePr-c
I-1036CF 35-ClNSMePr-c
I-1037CF 35-BrNSMePr-c
I-1038CF 35-MeNSMePr-c
I-1039MeHCHSMeSMe129-131
I-1040H5-ClNSMeSMe
I-1041H5-BrNSMeSMe
I-1042MeHNSMeSMe176-179
I-1043Me5-ClNSMeSMe186-189
I-1044Me5-BrNSMeSMe
I-1045Me5-MeNSMeSMe
I-1046CF 35-ClNSMeSMe144-146
I-1047CF 35-BrNSMeSMe
I-1048CF 35-MeNSMeMe106-109
TABLE 32 — m.p.
Compound(° C.) or
No.XYnAR 1R 2RI (n D 20 )
I-1049H5-BrNOMeSMe
I-1050Me5-ClNOMeSMe
I-1051Me5-BrNOMeSMe
I-1052Me5-MeNOMeSMe
I-1053CF 35-ClNOMeSMe
I-1054CF 35-BrNOMeSMe
I-1055CF 35-MeNOMeSMe
I-1056HHCHOMePh160-162
I-1057HHNOMePh
I-1058Me5-MeNOMePh165-168
I-1059CF 36-MeNOMePh150-153
I-1060HHCHClPh176-179
I-1061HHNClPh
I-1062HHCHClCl165-168
I-1063MeHCHClCl170-172
I-1064Me5,6-Cl 2CHClCl202-205
I-1065HHNClCl
I-1066MeHNClCl>300
I-1067HHCHClMe187-190
I-1068MeHCHClMe122-125
I-1069HHCHClN(Me) 2205-208
I-1070HHNClN(Me) 2
I-1071Me5-ClNN(Me) 2N(Me) 2203-206
I-1072HHCHOMeN(Me) 2129-132
I-1073HHCBrOMeOMe>300
I-1074HHCMeOMeOMe152-155
I-1075HHCMeClCl184-187
I-1076HHCOMeHH131-134
I-1077Me5-MeCOMeHH
I-1078Me5-ClCOMeHH
I-1079HHCHMeMe131-132
I-1080Me5-ClCHMeMe138-140
I-1081Me5-CF 3CHMeMe
I-1082HHCHMeCF 3107-110
TABLE 33
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
I-1083Me5-ClCHMeCF 3
I-1084Me5-ClNMeCF 3
I-1085HHCHMeEt60-63
I-1086H5-MeCHMeEt55-58
I-1087Me5-MeCHMeEt109-112
I-1088Me5-ClCHMeEt76-79
I-1089Me5-OMeCHMeEt
I-1090Me6-ClCHMeEt84-87
I-1091Cl5-ClCHMeEt
I-1092Cl5-MeCHMeEt
I-1093HHCHEtEt58-61
I-1094H5-MeCHEtEt68-71
I-1095Me5-MeCHEtEt76-79
I-1096Me5-ClCHEtEt78-80
I-1097Me5-OMeCHEtEt
I-1098Me6-ClCHEtEt80-83
I-1099Cl5-ClCHEtEt
I-1100Cl5-MeCHEtEt
I-1101HHCHMePr-c124-125
I-1102H5-MeCHMePr-c
I-1103Me5-MeCHMePr-c153-156
I-1104Me5-ClCHMePr-c119-122
I-1105Me5-OMeCHMePr-c
I-1106Me6-ClCHMePr-c110-113
I-1107Cl5-ClCHMePr-c
I-1108Cl5-MeCHMePr-c
I-1109HHCHEtPr-c
I-1110Me5-MeCHEtPr-c
I-1111Me5-ClCHEtPr-c
I-1112Me5-OMeCHEtPr-c
I-1113Me6-ClCHEtPr-c
I-1114Cl5-ClCHEtPr-c
I-1115Cl5-MeCHEtPr-c
I-1116HHCHEtEt
TABLE 34
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
I-1117Me5-MeCHEtEt
I-1118Me5-ClCHEtEt
I-1119Me5-OMeCHEtEt
I-1120Me6-ClCHEtEt
I-1121Cl5-ClCHEtEt
I-1122Cl5-MeCHEtEt
I-1123HHCHC≡CMeMe134-136
I-1124Me5-MeCHC≡CMeMe
I-1125Me5-ClCHC≡CMeMe
I-1126Me5-MeNC≡CMeMe
I-1127Me5-ClNC≡CMeMe
I-1128Cl5-ClCHC≡CMeMe
I-1129Cl5-MeCHC≡CMeMe
I-1130HHCHCH═CH 2Me
I-1131Me5-MeCHCH═CH 2Me
I-1132Me5-ClCHCH═CH 2Me
I-1133Me5-MeNCH═CH 2Me
I-1134Cl5-ClCHCH═CH 2Me
I-1135Cl5-MeCHCH═CH 2Me
I-1136HHCHCHOMe
I-1137Me5-ClCHCHOMe
I-1138Me5-ClNCHOMe
I-1139HHCHCOMeMe
I-1140Me5-ClCHCOMeMe
I-1141Me5-ClNCOMeMe
I-1142HHCHCH 2 OMeMe
I-1143Me5-ClCHCH 2 OMeMe
I-1144Me5-MeCHCH 2 OMeMe
I-1145HHNCH 2 OMeOMe
I-1146MeHCHCNCN
I-1147MeHCHCNMe187-189
I-1148MeHNCNCN
I-1149MeHNCNMe
I-1150MeHCHSO 2 MeSO 2 Me
TABLE 35
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
I-1151MeHNSO 2 MeSO 2 Me
I-1152MeHCHSO 2 MeMe183-186
TABLE 36
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-1HHCHOMeOMe
1-2MeHCHOMeOMe
1-3EtHCHOMeOMe
1-4PrHCHOMeOMe
1-5Pr-iHCHOMeOMe
1-6Pr-cHCHCMeOMe
1-7BuHCHOMeOMe
1-8BnHCHOMeOMe169-172
1-9Bn(4-Cl)HCHOMeOMe187-200
1-10Bn(4-Me)HCHOMeOMe157-158
1-11Bn(4-OMe)HCHOMeOMe
1-12CH═CH 2HCHOMeOMe147-149
1-13C≡CHHCHOMeOMe
1-14CH 2 OEtHCHOMeOMe
1-15CH 2 ClHCHOMeOMe125-126
1-16CH 2 CH 2 ClHCHOMeOMe162-165
1-17CH 2 IHCHOMeOMe
1-18CCl 3HCHOMeOMe
1-19CF 3HCHOMeOMe
1-20C 2 F 5HCHOMeOMe82-85
1-21PhHCHOMeOMe148-152
1-22Ph(4-Cl)HCHOMeOMe
1-23Ph(4-Me)HCHOMeOMe
1-24Ph(4-OMe)HCHOMeOMe
1-25HHNOMeOMe
1-26MeHNOMeOMe
TABLE 37
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-27EtHNOMeOMe
1-28PrHNOMeOMe
1-29Pr-iHNOMeOMe
1-30Pr-cHNOMeOMe
1-31BuHNOMeOMe
1-32BnHNOMeOMe
1-33Bn(4-Cl)HNOMeOMe
1-34Bn(4-Me)HNOMeOMe
1-35Bn(4-OMe)HNOMeOMe
1-36CH═CH 2HNOMeOMe
1-37C≡CHHNOMeOMe
1-38CH 2 OEtHNOMeOMe
1-39CH 2 ClHNOMeOMe
1-40CH 2 IHNOMeOMe
1-41CCl 3HNOMeOMe
1-42CF 3HNOMeOMe
1-43C 2 F 5HNOMeOMe
1-44PhHNOMeOMe
1-45Ph(4-Cl)HNOMeOMe
1-46Ph(4-Me)HNOMeOMe
1-47Ph(OMe)HNOMeOMe
1-48H6-MeCHOMeOMe
1-49H6-ClCHOMeOMe
1-50H5-FCHOMeOMe
1-51H5-ClCHOMeOMe
1-52H5-BrCHOMeOMe
1-53H5-MeCHOMeOMe
1-54H5-Bu-tCHOMeOMe
1-55H5-CF 3CHOMeOMe
1-56H5-OMeCHOMeOMe
1-57H5-OEtCHOMeOMe
1-58H5-OPrCHOMeOMe
1-59H5-OCF 3CHOMeOMe
TABLE 38
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-60H5-OCH 2 CH═CH 2CHOMeOMe
1-61H5-OCH 2 C≡CHCHOMeOMe
1-62H5-OPhCHOMeOMe
1-63H5-OPh(4-Cl)CHOMeOMe
1-64H5-OPh(4-Me)CHOMeOMe
1-65H5-OPh(4-OMe)CHOMeOMe
1-66H5-SMeCHOMeOMe
1-67H5-CH 2 OMeCHOMeOMe
1-68H5-COMeCHOMeOMe
1-69H5-COPhCHOMeOMe
1-70H5-CO 2 EtCHOMeOMe
1-71H5-PhCHOMeOMe
1-72H5-Ph(4-Cl)CHOMeOMe
1-73H5-Ph(4-Me)CHOMeOMe
1-74H5-Ph(4-OMe)CHOMeOMe
1-75H5-NO 2CHOMeOMe
1-76H5-NH 2CHOMeOMe
1-77H5-NHMeCHOMeOMe
1-78H5-NMe 2CHOMeOMe
1-79H5-CNCHOMeOMe
1-80H4-FCHOMeOMe
1-81H4-ClCHOMeOMe
1-82H4-MeCHOMeOMe
1-83H4-CF 3CHOMeOMe
1-84H4-OMeCHOMeOMe
1-85H4-CO 2 EtCHOMeOMe
1-86H4-COPhCHOMeOMe
1-87H3-MeCHOMeOMe
1-88H3-ClCHOMeOMe
1-89H4,5-Cl 2CHOMeOMe
1-90H4,5-Me 2CHOMeOMe
1-91H4,5-(OMe) 2CHOMeOMe
1-92H4-CF 3 , 6-BrCHOMeOMe
TABLE 39
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-93H4-CF 3 , 6-ClCHOMeOMe
1-94H4,5,6-F 3CHOMeOMe
1-95H6-MeNOMeOMe
1-96H6-ClNOMeOMe
1-97H5-FNOMeOMe
1-98H5-ClNOMeOMe
1-99H5-BrNOMeOMe
1-100H5-MeNOMeOMe
1-101H5-CF 3NOMeOMe
1-102H5-OMeNOMeOMe
1-103H5-OEtNOMeOMe
1-104H5-OPrNOMeOMe
1-105H5-OCF 3NOMeOMe
1-106H5-OCH 2 CH═CH 2NOMeOMe
1-107H5-OCH 2 C≡CHNOMeOMe
1-108H5-OPhNOMeOMe
1-109H5-SMeNOMeOMe
1-110H5-COPhNOMeOMe
1-111H5-CO 2 EtNOMeOMe
1-112H5-PhNOMeOMe
1-113H5-Ph(4-Cl)NOMeOMe
1-114H5-Ph(4-Me)NOMeOMe
1-115H5-Ph(4-OMe)NOMeOMe
1-116H5-NO 2NOMeOMe
1-117H5-NH 2NOMeOMe
1-118H5-NHMeNOMeOMe
1-119H5-NMe 2NOMeOMe
1-120H5-CNNOMeOMe
1-121H4-FNOMeOMe
1-122H4-ClNOMeOMe
1-123H4-MeNOMeOMe
1-124H4-CF 3NOMeOMe
1-125H4-OMeNOMeOMe
TABLE 40
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-126H4-NO 2NOMeOMe
1-127H4-CO 2 EtNOMeOMe
1-128H4-COPhNOMeOMe
1-129H3-MeNOMeOMe
1-130H3-ClNOMeOMe
1-131H4,5-Cl 2NOMeOMe
1-132H4,5-Me 2NOMeOMe
1-133H4,5-(OMe) 2NOMeOMe
1-134H4-CF 3 , 6-BrNOMeOMe
1-135H4-CF 3 , 6-ClNOMeOMe
1-136H4,5,6-F 3NOMeOMe
1-137Me6-MeCHOMeOMe
1-138Me6-ClCHOMeOMe
1-139Me6-FCHOMeOMe
1-140Me5-ClCHOMeOMe
1-141Me5-BrCHOMeOMe
1-142Me5-MeCHOMeOMe
1-143Me5-Bu-tCHOMeOMe
1-144Me5-CF 3CHOMeOMe
1-145Me5-OMeCHOMeOMe
1-146Me5-COPhCHOMeOMe
1-147Me5-PhCHOMeOMe
1-148Me5-NH 2CHOMeOMe
1-149Me5-NMe 2CHOMeOMe
1-150Me5-CNCHOMeOMe
1-151Me4-FCHOMeOMe
1-152Me4-ClCHOMeOMe
1-153Me4-MeCHOMeOMe
1-154Me4-CF 3CHOMeOMe
1-155Me4-OMeCHOMeOMe
1-156Me4-COPhCHOMeOMe
1-157Me4,5-Cl 2CHOMeOMe
1-158Me4,5-Me 2CHOMeOMe
TABLE 41
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-159Me4,5-(OMe) 2CHOMeOMe
1-160Me6-MeNOMeOMe
1-161Me6-ClNOMeOMe
1-162Me5-FNOMeOMe
1-163Me5-ClNOMeOMe
1-164Me5-BrNOMeOMe
1-165Me5-MeNOMeOMe180-183
1-166Me5-EtNOMeOMe
1-167Me5-PrNOMeOMe
1-168Me5-Pr-iNOMeOMe
1-169Me5-Bu-tNOMeOMe
1-170Me5-CH═CH 2NOMeOMe
1-171Me5-C≡CBuNOMeOMe
1-172Me5-CF 3NOMeOMe
1-173Me5-OMeNOMeOMe
1-174Me5-SMeNOMeOMe
1-175Me5-COPhNOMeOMe
1-176Me5-PhNOMeOMe
1-177Me5-NH 2NOMeOMe
1-178Me5-NMe 2NOMeOMe
1-179Me5-CNNOMeOMe
1-180Me4-FNOMeOMe
1-181Me4-ClNOMeOMe
1-182Me4-MeNOMeOMe
1-183Me4-CF 3NOMeOMe
1-184Me4-OMeNOMeOMe
1-185Me4-OEtNOMeOMe
1-186Me4-OPrNOMeOMe
1-187Me4-CO 2 EtNOMeOMe
1-188Me4-COPhNOMeOMe
1-189Me4,5-Cl 2NOMeOMe
1-190Me4,6-Me 2NOMeOMe
1-191Me4,5-Me 2NOMeOMe
TABLE 42
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-192Me4,5-(OMe) 2NOMeOMe
1-193CF 35-FCHOMeOMe158-160
1-194CF 35-ClCHOMeOMe150-151
1-195CF 35-BrCHOMeOMe
1-196CF 35-MeCHOMeOMe144-147
1-197CF 35-CF 3CHOMeOMe168-171
1-198CF 35-OMeCHOMeOMe
1-199CF 35-OEtCHOMeOMe122-125
1-200CF 35-OPrCHOMeOMe
1-201CF 35-NMe 2CHOMeOMe
1-202CF 35-CNCHOMeOMe
1-203CF 34-FCHOMeOMe
1-204CF 34-ClCHOMeOMe
1-205CF 34-MeCHOMeOMe
1-206CF 34,5-(OMe) 2CHOMeOMe
1-207CF 35-FNOMeOMe202-205
1-208CF 35-ClNOMeOMe
1-209CF 35-BrNOMeOMe
1-210CF 35-MeNOMeOMe195-198
1-211CF 35-EtNOMeOMe182-185
1-212CF 35-PrNOMeOMe141-144
1-213CF 35-Pr-iNOMeOMe193-196
1-214CF 35-Bu-tNOMeOMe215-218
1-215CF 35-CF 3NOMeOMe
1-216CF 35-OMeNOMeOMe183-185
1-217CF 35-OEtNOMeOMe
1-218CF 35-OPrNOMeOMe
1-219CF 35-OCF 3NOMeOMe188-191
1-220CF 35-SMeNOMeOMe
1-221CF 35-NHMeNOMeOMe
1-222CF 35-NMe 2NOMeOMe
1-223CF 35-CNNOMeOMe
1-224CF 35-CO 2 MeNOMeOMe186-189
TABLE 43
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-225CF 35-INOMeOMe169-172
1-226CF 34-FNOMeOMe
1-227CF 34-ClNOMeOMe
1-228CF 36-MeNOMeOMe
1-229CF 34,5-(OMe) 2NOMeOMe
1-230Et5-FCHOMeOMe
1-231Et5-ClCHOMeOMe
1-232Et5-MeCHOMeOMe
1-233Et5-CF 3CHOMeOMe
1-234Et5-OMeCHOMeOMe
1-235Et5-CNCHOMeOMe
1-236Et4-FCHOMeOMe
1-237Et4-ClCHOMeOMe
1-238Et4-MeCHOMeOMe
1-239Et4,5-(OMe) 2CHOMeOMe
1-240Et5-FNOMeOMe
1-241Et5-ClNOMeOMe
1-242Et5-MeNOMeOMe
1-243Et5-CF 3NOMeOMe
1-244Et5-OMeNOMeOMe
1-245Et5-CNNOMeOMe
1-246Et4-FNOMeOMe
1-247Et4-ClNOMeOMe
1-248Et4-MeNOMeOMe
1-249Et4,5-(OMe) 2NOMeOMe
1-250Pr5-ClNOMeOMe137-140
1-251Pr-i5-ClNOMeOMe149-152
1-252Pr-c5-ClNOMeOMe181-184
1-253CH 2 OMe5-ClNOMeCMe
1-254Ph5-ClNOMeOMe176-179
1-255Ph5-BrNOMeOMe
1-256Ph(4-Cl)5-ClNOMeOMe
1-257Ph(4-Me)5-ClNOMeOMe
TABLE 44
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-258Ph(4-OMe)5-ClNOMeOMe
1-259Bn5-ClNOMeOMe
1-260CF 2 Cl5-MeNOMeOMe
1-261CF 2 Cl5-ClNOMeOMe
1-262CF 2 Cl5-BrNOMeOMe
1-263CF 2 Cl5-OMeNOMeOMe
1-264CH 2 Cl5-MeNOMeOMe
1-265CH 2 Cl5-ClNOMeOMe
1-266CH 2 Cl5-BrNOMeOMe
1-267CH 2 Cl5-OMeNOMeOMe
1-268C 2 F 55-MeNOMeOMe
1-269C 2 F 55-ClNOMeOMe
1-270C 2 F 55-BrNOMeOMe
1-271C 2 F 55-OMeNOMeOMe
1-272Ph(4-Cl)5-OMeCHOMeOMe187-200
1-273CH 2 OMe5-ClNOMeOMe183-186
1-274CF 35-MeNOMeOEt
1-275CF 35-ClNOMeOEt
1-276CF 35-BrNOMeOEt
1-277CF 2 Cl5-ClNOMeOEt
1-278CF 2 Cl5-BrNOMeOEt
1-279CF 2 Cl5-MeNOMeOEt
1-280CH 2 Cl5-ClNOMeOEt
1-281CH 2 Cl5-BrNOMeOEt
1-282CH 2 Cl5-MeNOMeOEt
1-283C 2 F 55-ClNOMeOEt
1-284C 2 F 55-BrNOMeOEt
1-285C 2 F 55-MeNOMeOEt
1-286Me5-FCHOEtOEt
1-287Me5-ClCHOEtOEt
1-288Me5-BrCHOEtOEt
1-289Me5-MeCHOEtOEt
1-290Me5-CF 3CHOEtOEt
TABLE 45
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-291Me5-FNOEtOEt
1-292Me5-ClNOEtOEt
1-293Me5-BrNOEtOEt
1-294Me5-MeNOEtOEt
1-295Me5-CF 3NOEtOEt
1-296CF 35-FCHOEtOEt
1-297CF 35-ClCHOEtOEt
1-298CF 35-BrGHOEtOEt
1-299CF 35-MeCHOEtOEt
1-300CF 35-CF 3CHOEtOEt
1-301CF 35-OMeNOEtOEt159-161
1-302CF 35-ClNOEtOEt194-197
1-303CF 35-BrNOEtOEt191-194
1-304CF 35-MeNOEtOEt201-204
1-305CF 35-CF 3NOEtOEt
1-306PhHNOEtOEt
1-307Ph(4-Cl)HNOEtOEt
1-308Ph(4-Me)HNOEtOEt
1-309Ph(4-OMe)HNOEtOEt
1-310Ph5-ClNOEtOEt
1-311Ph(4-Cl)5-ClNOEtOEt
1-312Ph(4-Me)5-ClNOEtOEt
1-313Ph(4-OMe)5-ClNOEtOEt
1-314Ph5-BrNOEtOEt
1-315Ph(4-Cl)5-BrNOEtOEt
1-316Ph(4-Me)5-BrNOEtOEt
1-317Ph(4-OMe)5-BrNOEtOEt
1-318HHCHOPrOPr
1-319Me5-ClNOPrOPr
1-320Me5-BrNOPrOPr
1-321Me5-MeNOPrOPr
1-322CF 35-ClNOPrOPr150-153
1-323CF 35-BrNOPrOPr
TABLE 46
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-324CF 35-MeNOPrOPr
1-325HHCHOPr-iOPr-i
1-326Me5-ClCHOPr-iOPr-i
1-327Me5-MeCHOPi-iOPr-i
1-328Me5-ClNOPr-iOPr-i
1-329Me5-BrNOPr-iOPr-i
1-330Me5-MeNOPr-iOPr-i
1-331CF 35-ClNOPr-iOPr-i198-201
1-332CF 35-BrNOPr-iOPr-i
1-333CF 35-MeNOPr-iOPr-i
1-334Me5-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2
1-335Me5-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
1-336Me5-MeNOCH 2 CH═CH 2OCH 2 CH═CH 2
1-337CF 35-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2121-124
1-338CF 35-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
1-339CF 35-MeNOCH 2 CH═CH 2OCH 2 CH═CH 2
1-340Me5-ClNOCH 2 C≡CHOCH 2 C≡CH
1-341Me5-BrNOCH 2 C≡CHOCH 2 C≡CH
1-342Me5-MeNOCH 2 C≡CHOCH 2 C≡CH
1-343CF 35-ClNOCH 2 C≡CHOCH 2 C≡CH
1-344CF 35-BrNOCH 2 C≡CHOCH 2 C≡CH
1-345CF 35-MeNOCH 2 C≡CHOCH 2 C≡CH
1-346Me5-ClCHOCH 2 CNOCH 2 CN
1-347Me5-MeCHOCH 2 CNOCH 2 CN
1-348Me5-ClNOCH 2 CNOCH 2 CN
1-349Me5-BrNOCH 2 CNOCH 2 CN
1-350Me5-MeNOCH 2 CNOCH 2 CN
1-351CF 35-ClNOCH 2 CNOCH 2 CN
1-352CF 35-BrNOCH 2 CNOCH 2 CN
1-353CF 35-MeNOCH 2 CNOCH 2 CN
1-354Me5-ClCHOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-355Me5-MeCHOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-356H5-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
TABLE 47
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-357Me5-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-358Me5-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-359Me5-MeNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-360CF 35-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-361CF 35-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-362CF 35-MeNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
1-363H5-BrNOCH 2 Pr-cOCH 2 Pr-c
1-364Me5-ClNOCH 2 Pr-cOCH 2 Pr-c
1-365Me5-BrNOCH 2 Pr-cOCH 2 Pr-c
1-366Me5-MeNOCH 2 Pr-cOCH 2 Pr-c
1-367CF 35-ClNOCH 2 Pr-cOCH 2 Pr-c
1-368CF 35-BrNOCH 2 Pr-cOCH 2 Pr-c
1-369CF 35-MeNOCH 2 Pr-cOCH 2 Pr-c
1-370HHCHOBnOBn
1-371HHNOBnOBn
1-372HHNOBn(4-Cl)OBn(4-Cl)
1-373HHNOBn(4-Me)OBn(4-Me)
1-374HHNOBn(4-OMe)OBn(4-OMe)
1-375HHCHOMeOPh
1-376HHNOMeOPh
1-377HHNOMeOPh(4-Cl)
1-378HHNOMeOPh(4-Me)
1-379HHNOMeOPh(4-OMe)
1-380HHCHOMeOCHF 2
1-381HHNOMeOCHF 2
1-382Me5-ClCHOMeH
1-383Me5-MeCHOMeH
1-384Me5-CF 3CHOMeH
1-385Me5-OMeCHOMeH
1-386CF 35-ClCHOMeH125-128
1-387CF 35-MeCHOMeH130-133
1-388CF 35-CF 3CHOMeH
1-389CF 35-OMeCHOMeH153-156
TABLE 48
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-390CF 35-ClCHOEtH
1-391CF 35-MeCHOEtH125-127
1-392CF 35-OMeCHOEtH
1-393Me5-ClCHOMeMe
1-394Me5-MeCHOMeMe
1-395Me5-CF 3CHOMeMe
1-396CF 35-ClCHOMeMe
1-397CF 35-MeCHOMeMe
1-398CF 35-OMeCHOMeMe
1-399Me5-ClNOMeMe
1-400Me5-MeNOMeMe
1-401Me5-CF 3NOMeMe
1-402CF 35-ClNOMeMe
1-403CF 35-MeNOMeMe192-195
1-404CF 35-OMeNOMeMe
1-405CF 35-ClNOMePr
1-406CF 35-BrNOMePr
1-407CF 35-MeNOMePr149-152
1-408CF 35-ClNOMePr-c
1-409CF 35-BrNOMePr-c
1-410CF 35-MeNOMePr-c103-106
1-411CF 35-ClNOEtPr-c
1-412CF 35-MeNOEtPr-c
1-413CF 35-CF 3NOEtPr-c
1-414Me5-ClCHOEtMe
1-415Me5-MeCHOEtMe
1-416Me5-CF 3CHOEtMe
1-417Me5-OMeCHOEtMe
1-418CF 35-ClCHOEtMe
1-419CF 35-MeCHOEtMe
1-420CF 35-OMeCHOEtMe136-139
1-421Me5-ClNOEtMe
1-422Me5-BrNOEtMe
TABLE 49 — m.p.
Compound(° C.) or
No.XYnAR 1R 2RI (n D 20 )
1-423Me5-MeNOEtMe
1-424Me5-CF 3NOEtMe
1-425CF 35-ClNOEtMe
1-426CF 35-BrNOEtMe
1-427CF 35-MeNOEtMe
1-428CF 35-ClCHOCH 2 CH═CH 2Me
1-429CF 35-MeCHOCH 2 CH═CH 2Me
1-430CF 35-OMeCHOCH 2 CH═CH 2Me
1-431CF 35-ClNOCH 2 CH═CH 2Me
1-432CF 35-MeNOCH 2 CH═CH 2Me175-178
1-433CF 35-OMeNOCH 2 CH═CH 2Me
1-434CF 35-MeCHSMeMe
1-435CF 35-ClCHSMeMe
1-436CF 35-MeNSMeMe196-199
1-437CF 35-ClNSMeMe157-160
1-438CF 35-ClNOMeEt
1-439CF 35-BrNOMeEt
1-440CF 35-MeNOMeEt
1-441CF 35-ClNOEtEt
1-442CF 35-BrNOEtEt
1-443CF 35-MeNOEtEt
1-444Me5-ClNSMeSMe
1-445Me5-BrNSMeSMe
1-446Me5-MeNSMeSMe
1-447CF 35-ClNSMeSMe
1-448CF 35-BrNSMeSMe
1-449CF 35-MeNSMeSMe
1-450Me5-ClNOMeSMe
1-451Me5-BrNOMeSMe
1-452CF 35-ClNOMeSMe
1-453CF 35-BrNOMeSMe
1-454CF 35-MeNOMeSMe
1-455Me5-MeNOMePh
TABLE 50 — m.p.
Compound(° C.) or
No.XYnAR 1R 2RI (n D 20 )
1-456CF 35-MeNOMePh219-222
1-457MeHCHClCl
1-458Me4,5-Cl 2CHClCl
1-459MeHNClCl
1-460MeHCHClMe
1-461Me5-ClNNMe 2NMe 2
1-462CF 35-ClNNMe 2NMe 2219-222
1-463HHCHOMeNMe 2
1-464HHCBrOMeOMe
1-465HHCMeClCl
1-466Me5-MeCOMeHH
1-467Me5-ClCOMeHH
1-468Me5-ClCHMeMe
1-469Me5-CF 3CHMeMe
1-470Me5-ClCHMeCF 3
1-471Me5-MeCHMeEt
1-472Me5-ClCHMeEt
1-473CF 35-MeCHMeEt
1-474CF 35-ClCHMeEt
1-475Me5-MeCHMePr-c
1-476Me5-ClCHMePr-c
1-477CF 35-MeCHMePr-c
1-478CF 35-ClCHMePr-c
1-479CF 35-ClCHC≡CMeMe
1-480CF 35-ClNC≡CMeMe
1 481CF 35-ClCHCH═CH 2Me
1-482CF 35-ClNCH═CH 3Me
1-483Me5-ClCHCHOMe
1-484Me5-ClNCHOMe
1-485Me5-ClCHCOMeMe
1-486Me5-ClNCOMeMe
1-487Me5-ClCHCH 2 OMeMe
1-488Me5-MeCHCH 2 OMeMe
TABLE 51
Compoundm.p. (° C.)
No.XYnAR 1R 2or RI (n D 20 )
1-489MeHCHCNCN
1-490MeHCHCNMe
1-491MeHNCNCN
1-492MeHNCNMe
1-493MeHCHSO 2 MeSO 2 Me
1-494MeHNSO 2 MeSO 2 Me
1-495MeHCHSO 2 MeMe
TABLE 52
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-13-MeCHOMeOMe
2-23-ClCHOMeOMe
2-34-FCHOMeOMe194-196
2-44-ClCHOMeOMe188-190
2-54-BrCHOMeOMe191-194
2-64-MeCHOMeOMe158-161
2-74-Bu-tCHOMeOMe
2-84-CF 3CHOMeOMe178-180
2-94-OMeCHOMeOMe189-190
2-104-OEtCHOMeOMe178-180
2-114-OPrCHOMeOMe
2-124-OCF 3CHOMeOMe144-147
2-134-OCH 2 CH═CH 2CHOMeOMe
2-144-OCH 2 C≡CHCHOMeOMe
2-154-OPhCHOMeOMe
2-164-OPh(4-Cl)CHOMeOMe
2-174-OPh(4-Me)CHOMeOMe
2-184-OPh(4-OMe)CHOMeOMe
2-194-SMeCHOMeOMe
2-204-CH 2 OMeCHOMeOMe
2-214-COMeCHOMeOMe
2-224-COPhCHOMeOMe
2-234-CO 2 EtCHOMeOMe
2-244-PhCHOMeOMe
TABLE 53
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-254-Ph(4-Cl)CHOMeOMe
2-264-Ph(4-Me)CHOMeOMe
2-274-Ph(4-OMe)CHOMeOMe
2-284-NO 2CHOmeOMe
2-294-NH2CHOMeOMe
2-304-NHMeCHOMeOMe
2-314-NMe 2CHOMeOMe
2-324-CNCHOMeOMe241-244
2-335-FCHOMeOMe
2-345-ClCHOMeOMe
2-355-MeCHOMeOMe
2-365-CF 3CHOMeOMe
2-375-OMeCHOMeOMe
2-385-CO 2 MeCHOMeOMe
2-395-COPhCHOMeOMe
2-406-MeCHOMeOMe136-139
2-416-ClCHOMeOMe
2-424,5-Cl 2CHOMeOMe
2-434,5-Me 2CHOMeOMe
2-444,5-(OMe) 2CHOMeOMe
2-454,6-Me 2CHOMeOMe139-142
2-463-Br, 5-CF 3CHOMeOMe
2-473-Cl, 5-CF 3CHOMeOMe
2-483,4,5-F 3CHOMeOMe
2-49HNOMeOMe177-180
2-503-MeNOMeOMe
2-513-ClNOMeOMe
2-524-FNOMeOMe184-187
2-534-ClNOMeOMe206-208
2-544-BrNOMeOMe
2-554-INOMeOMe218-221
TABLE 54
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-564-MeNOMeOMe189-191
2-574-EtNOMeOMe146-149
2-584-PrNOMeOMe170-173
2-594-CF 3NOMeOMe
2-604-Bu-tNOMeOMe118-121
2-614-C≡CBu-tNOMeOMe117-120
2-624-OMeNOMeOMe197-199
2-634-OEtNOMeOMe
2-644-OPrNOMeOMe
2-654-OCF 3NOMeOMe119-122
2-664-OCH 2 CH═CH 2NOMeOMe
2-674-OCH 2 C≡CHNOMeOMe
2-684-OPhNOMeOMe
2-694-SMeNOMeOMe
2-704-COPhNOMeOMe221-224
2-714-CO 2 MeNOMeOMe289-292
2-724-PhNOMeOMe
2-734-Ph(4-Cl)NOMeOMe
2-744-Ph(4-Me)NOMeOMe
2-754-Ph(4-OMe)NOMeOMe
2-764-NO 2NOMeOMe
2-774-NH 2NOMeOMe
2-784-NHMeNOMeOMe
2-794-NMe 2NOMeOMe155-158
2-804-CNNOMeOMe189-201
2-815-FNOMeOMe
2-825-ClNOMeOMe
2-835-MeNOMeOMe151-154
2-845-CF 3NOMeOMe
2-855-OMeNOMeOMe
2-865-NO 2NOMeOMe
TABLE 55
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-875-CO 2 EtNOMeOMe
2-885-COPhNOMeOMe
2-896-MeNOMeOMe
2-906-ClNOMeOMe
2-914,5-Cl 2NOMeOMe
2-924,5-Me 2NOMeOMe
2-934,5-(OMe) 2NOMeOMe
2-943-Br, 5-CF 3NOMeOMe
2-953-Cl, 5-CF 3NOMeOMe
2-963,4,5-F 3NOMeOMe
2-974-MeNOMeOEt173-175
2-984-ClNOMeOEt130-132
2-994-BrNOMeOEt
2-100HCHOEtOEt92-95
2-1014-FCHOEtOEt131-134
2-1024-ClCHOEtOEt147-149
2-1034-BrCHOEtOEt
2-1044-MeCHOEtOEt147-150
2-1054-CF 3CHOEtOEt134-137
2-1064-FNOEtOEt
2-1074-ClNOEtOEt
2-1084-BrNOEtOEt
2-1094-MeNOEtOEt
2-1104-CF 3NOEtOEt
2-1114-ClNOPrOPr
2-1124-ClCHOPr-iOPr-i
2-1134-MeCHOPr-iOPr-i
2-1144-ClNOPr-iOPr-i
2-1154-BrNOPr-iOPr-i
2-1164-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2
2-1174-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
TABLE 56 — m.p.
Compound(° C.) or
No.YnAR 1R 2RI (n D 20 )
2-1184-ClNOCH 2 C≡CHOCH 2 C≡CH
2-1194-BrNOCH 2 C≡CHOCH 2 C≡CH
2-1204-ClNOCH 2 CNOCH 2 CN
2-1214-BrNOCH 2 CNOCH 2 CN
2-1224-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
2-1234-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
2-1244-BrNOCH 2 Pr-cOCH 2 Pr-c
2-1254-ClNOCH 2 Pr-cOCH 2 Pr-c65-68
2-126HCHOBnOBn
2-127HNOBnOBn
2-128HNOBn(4-Cl)OBn(4-Cl)
2-129HNOBn(4-Me)OBn(4-Me)
2-130HNOBn(4-OMe)OBn(4-OMe)
2-131HCHOMeOPh
2-132HNOMeOPh
2-133HNOMeOPh(4-Cl)
2-134HNOMeOPh(4-Me)
2-135HNOMeOPh(4-OMe)
2-136HCHOMeOCHF 2
2-137HNOMeOCHF 2
2-1384-ClCHOMeH136-139
2-1394-MeCHOMeH136-139
2-1404-ClCHOEtH118-119
2-1414-MeCHOEtH99-100
2-1424-ClCHOMeMe
2-1434-MeCHOMeMe
2-1444-CF 3CHOMeMe155-158
2-1454-ClNOMeMe
2-1464-MeNOMeMe
2-1474-ClNOMePr
2-1484-MeNOMePr116-119
TABLE 57
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-1494-ClNOMePr-c
2-1504-BrNOMePr-c
201514-MeNOMePr-c130133
2-1524-ClNOEtPr-c
2-1534-MeNOEtPr-c
2-1544-ClNOMeEt109-112
2-1554-BrNOMeEt113-116
2-1564-MeNOMeEt
2-1574-ClNOEtEt
2-1584-BrNOEtEt
2-1594-MeNOEtEt
2-1604-MeNOPrMe175-178
2-1614-ClNOPrMe
2-1624-MeCHMeEt75-78
2-1634-ClCHMeEt
2-1644-MeCHEtEt64-67
2-1654-ClCHEtEt
2-1664-MeNMeSMe174-177
2-1674-ClNSMeSMe179-182
2-1684-BrNSMeSMe
2-1694-MeNSMeSMe
2-1704-ClNOMeSMe
2-1714-MeNOMeSMe
2-1724-MeNOMePh165-168
2-1734-ClNNMe 2NMe 2>300
2-174HCBrOMeOMe
2-175HCMeClCl
2-1764-MeCOMeHH
2-1774-ClCOMeHH
2-1784-MeNClPh106-109
2-1794-ClNClPh
TABLE 58
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
2-1804-ClCHC≡CMeMe
2-1814-ClNC≡CMeMe
2-1824-ClCHCH═CH 2Me
2-1834-ClNCH═CH 2Me
2-1844-ClCHCHOMe
2-1854-ClNCHOMe
2-1864-ClCHCOMeMe
2-1874-ClNCOMeMe
2-1884-ClCHCH 2 OMeMe
2-1894-MeCHCH 2 OMeMe
2-190HCHCNCN
2-191HCHCNMe
2-192HNCNCN
2-193HNCNMe
2-194HCHSO 2 MeSO 2 Me
2-195HNSO 2 MeSO 2 Me
2-196HCHSO 2 MeMe
TABLE 59
Compoundm.p. (° C.)
No.YnAR 1R 2or RI (n D 20 )
3-13-MeCHOMeOMe
3-23-ClCHOMeOMe
3-34-FCHOMeOMe120-123
3-44-ClCHOMeOMe
3-54-BrCHOMeOMe117-118
3-64-MeCHOMeOMe128-129
3-74-Bu-tCHOMeOMe
3-84-CF 3CHOMeOMe113-115
3-94-OMeCHOMeOMe
3-104-OEtCHOMeOMe129-132
3-114-OPrCHOMeOMe
3-124-OCF 3CHOMeOMe85-88
3-134-OCH 2 CH═CH 2CHOMeOMe
3-144-OCH 2 C≡CHCHOMeOMe
3-154-OPhCHOMeOMe
3-164-OPh(4-Cl)CHOMeOMe
3-174-OPh(4-Me)CHOMeOMe
3-184-OPh(4-OMe)CHOMeOMe
3-194-SMeCHOMeOMe
3-204-CH 2 OMeCHOMeOMe
3-214-COMeCHOMeOMe
3-224-COPhCHOMeOMe
3-234-CO 2 EtCHOMeOMe
3-244-PhCHOMeOMe130-132
TABLE 60 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-254-Ph(4-Cl)CHOMeOMe
3-264-Ph(4-Me)CHOMeOMe
3-274-Ph(4-OMe)CHOMeOMe
3-284-NO 2CHOMeOMe
3-294-NH 2CHOMeOMe
3-304-NHMeCHOMeOMe
3-314-NMe 2CHOMeOMe
3-324-CNCHOMeOMe166-169
3-335-FCHOMeOMe
3-345-ClCHOMeOMe124-125
3-355-MeCHOMeOMe91-94
3-365-CF 3CHOMeOMe
3-375-OMeCHOMeOMe
3-385-CO 2 MeCHOMeOMe
3-395-COPhCHOMeOMe
3-406-MeCHOMeOMe
3-416-ClCHOMeOMe
3-424,5-Cl 2CHOMeOMe
3-434,6-Me 2CHOMeOMe145-147
3-444,5-Me 2CHOMeOMe
3-454,5-(OMe) 2CHOMeOMe
3-463-Br,5-CF 3CHOMeOMe
3-473-Cl,5-CF 3CHOMeOMe
3-483,4,5-F 3CHOMeOMe
3-49HNOMeOMe152-155
3-503-MeNOMeOMe
3-513-ClNOMeOMe
3-524-FNOMeOMe183-186
3-534-ClNOMeOMe202-205
3-544-BrNOMeOMe200-203
3-554-INOMeOMe191-194
TABLE 61 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-564-MeNOMeOMe180-183
3-574-EtNOMeOMe123-126
3-584-PrNOMeOMe136-139
3-594-CF 3NOMeOMe177-180
3-604-Bu-tNOMeOMe140-143
3-614-C-≡CBu-tNOMeOMe161-164
3-624-OMeNOMeOMe182-185
3-634-OEtNOMeOMe
3-644-OPrNOMeOMe
3-654-OCF 3NOMeOMe
3-664-OCH 2 CH═CH 2NOMeOMe
3-674-OCH 2 C≡CHNOMeOMe
3-684-OPhNOMeOMe
3-694-SMeNOMeOMe
3-704-COPhNOMeOMe175-178
3-714-CO 2 MeNOMeOMe197-200
3-724-PhNOMeOMe
3-734-Ph(4-Cl)NOMeOMe
3-744-Ph(4-Me)NOMeOMe
3-754-Ph(4-OMe)NOMeOMe
3-764-NO 2NOMeOMe
3-774-NH 2NOMeOMe
3-784-NHMeNOMeOMe
3-794-NMe 2NOMeOMe115-118
3-804-CNNOMeOMe215-218
3-815-FNOMeOMe
3-825-ClNOMeOMe
3-835-MeNOMeOMe131-134
3-845-CF 3NOMeOMe
3-855-OMeNOMeOMe
3-865-NO 2NOMeOMe
TABLE 62 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-875-CO 2 EtNOMeOMe
3-885-COPhNOMeOMe
3-896-MeNOMeOMe
3-906-ClNOMeOMe
3-914,5-Cl 2NOMeOMe
3-924,5-Me 2NOMeOMe
3-934,5-(OMe) 2NOMeOMe
3-943-Br,5-CF 3NOMeOMe
3-953-Cl,5-CF 3NOMeOMe
3-963,4,5-F 3NOMeOMe
3-974-MeNOMeOEt134-137
3-984-ClNOMeOEt132-135
3-994-BrNOMeOEt140-142
3-100HCHOEtOEt146-148
3-1014-FCHOEtOEt
3-1024-ClCHOEtOEt
3-1034-BrCHOEtOEt
3-1044-MeCHOEtOEt
3-1054-CF 3CHOEtOEt167-170
3-1064-FNOEtOEt
3-1074-ClNOEtOEt163-166
3-1084-BrNOEtOEt172-175
3-1094-MeNOEtOEt158-161
3-1104-Bu-tNOEtOEt128-129
3-1114-OMeNOEtOEt128-129
3-1124-CF 3NOEtOEt
3-1134-ClNOPrOPr145-148
3-1144-ClCHOPr-iOPr-i
3-1154-MeCHOPr-iOPr-i
3-1164-ClNOPr-iOPr-i179-182
3-1174-BrNOPr-iOPr-i
TABLE 63 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-1184-ClNOCH 2 CH═CH 2OCH 2 CH═CH 2
3-1194-BrNOCH 2 CH═CH 2OCH 2 CH═CH 2
3-1204-ClNOCH 2 C≡CHOCH 2 C≡CH
3-1214-BrNOCH 2 C≡CHOCH 2 C≡CH
3-1224-ClNOCH 2 CNOCH 2 CN
3-1234-BrNOCH 2 CNOCH 2 CN
3-1244-BrNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
3-1254-ClNOCH 2 CH 2 OMeOCH 2 CH 2 OMe
3-1264-BrNOCH 2 Pr-cOCH 2 Pr-c
3-1274-ClNOCH 2 Pr-cOCH 2 Pr-c156-159
3-128HCHOBnOBn
3-129HNOBnOBn
3-130HNOBn(4-Cl)OBn(4-Cl)
3-131HNOBn(4-Me)OBn(4-Me)
3-132HNOBn(4-OMe)OBn(4-OMe)
3-133HCHOMeOPh
3-134HNOMeOPh
3-135HNOMeOPh(4-Cl)
3-136HNOMeOPh(4-Me)
3-137HNOMeOPh(4-OMe)
3-138HCHOMeOCHF 2
3-139HNOMeOCHF 2
3-1404-ClCHOMeH136-139
3-1414-MeCHOMeH126-129
3-1424-ClCHOEtH113-115
3-1434-MeCHOEtH103-105
3-1444-ClCHOMeMe
3-1454-MeCHOMeMe
3-1464-CF 3CHOMeMe134-137
3-1474-ClNOMeMe
3-1484-MeNOMeMe202-205
TABLE 64 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-1494-ClNOMePr
3-1504-MeNOMePr133-136
3-1514-ClNOMePr-c
3-1524-BrNOMePr-c163-165
3-1534-MeNOMePr-c56-59
3-1544-ClNOEtPr-c163-166
3-1554-MeNOEtPr-c105-108
3-1564-ClNOMeEt155-158
3-1574-BrNOMeEt162-165
3-1584-MeNOMeEt171-174
3-1594-ClNOEtEt
3-1604-BrNOEtEt
3-1614-MeNOEtEt
3-1624-MeNOPrMe
3-1634-ClNOPrMe
3-1644-MeCHMeEt92-95
3-1654-ClCHMeEt
3-1664-MeCHEtEt91-94
3-1674-ClCHEtEt
3-1684-MeNMeSMe180-183
3-1694-ClNSMeSMe192-195
3-1704-BrNSMeSMe
3-1714-MeNSMeSMe
3-1724-ClNOMeSMe
3-1734-MeNOMeSMe
3-1744-MeNOMePh170-173
3-1754-ClNNMe 2NMe 2176-179
3-176HCBrOMeOMe
3-177HCMeClCl
3-1784-MeCOMeHH
3-1794-ClCOMeHH
TABLE 65 — m.p. (° C.) or
CompoundRI
No.YnAR 1R 2(n D 20 )
3-1804-MeNClPh
3-1814-ClNClPh
3-1824-ClCHC≡CMeMe
3-1834-ClNC≡CMeMe
3-1844-ClCHCH═CH 2Me
3-1854-ClNCH═CH 2Me
3-1864-ClCHCHOMe
3-1874-ClNCHOMe
3-1884-ClCHCOMeMe
3-1894-ClNCOMeMe
3-1904-ClCHCH 2 OMeMe
3-1914-MeCHCH 2 OMeMe
3-192HCHCNCN
3-193HCHCNMe
3-194HNCNCN
3-195HNCNMe
3-196HCHSO 2 MeSO 2 Me
3-197HNSO 2 MeSO 2 Me
3-198HCHSO 2 MeMe
TABLE 66 — Compound
No.1 H-NMR δ (ppm), solvent CDCl 3
I-302.99(6H,s);4.03(6H,s);5.99(1H,8);7.03-7.09(1H,m);7.17-7.22(1H,m);
7.48-7.51(1H,m);7.84-7.85(1H,m);8.01(1H,s)
I-343.64(6H,s);5.92(1H,s);7.42-7.36(5H,m);7.56-7.60(2H,m);
7.58-7.88(1H,m);8.20-8.23(1H,m)
I-8401.41(6H,d,J=6.3Hz);2.52(3H,s);2.98(3H,s);5.39-5.47(1H,m);
6.46(1H,s);7.26-7.33(2H,m);7.69-7.72(1H,m);8.25-8.28(1H,m)
I-8721.01(3H,t,J=7.5Hz);1.49-1.57(2H,m);1.80-1.87(2H,m);2.51(3H,s);
4.50(2H,t,J=6.57Hz);6.45(1H,s);7.33-7.43(2H,m);7.82-7.85(1H,m);
8.55-8.59(1H,m);9.05(1H,s)
I-9061.66-2.11(8H,m);2.45(3H,8);5.51-5.56(1H,m);6.36(1H,s);
7.28-7.41(2H,m);7.81-7.83(1H,m);8.45-8.52(1H,m);9.05(1H,s)
I-9071.65-2.04(8H,m);2.51(3H,s);3.98(3H,s);5.51-5.55(1H,m);6.46(1H,s);
7.26-7.34(2H,m);7.68-7.73(1H,m);8.25-8.31(1H,m)
I-9591.03(3H,t,J=7.41Hz);1.81-1.89(2H,m);2.76(2H,t,J=7.14Hz);
3.00(3H,s);4.08(3H,s);6.51(1H,s);7.27-7.33(2H,m);7.70-7.73(1H,m);
8.28-8.34(1H,m)
I-9601.03(3H,t,J=7.29Hz);1.81-1.89(2H,m);2.77(2H,t,J=7.29Hz);
4.07(3H,s);6.58(1H,s);7.30-7.37(2H,m);7.71-7.74(1H,m);
8.00-8.05(1H,m)
TABLE 67 — Evaluation
ANo diseased area
BDiseased area of less than 25%
CDiseased area of at least 25% but less than 50%
DDiseased area of at least 50%
TABLE 68
Com-BiologicalCom-BiologicalCom-Biological
poundeffective-poundeffective-poundeffective-
No.nessNo.nessNoness
I-1AI-189AI-307A
I-2AI-192BI-309A
I-3AI-195BI-310A
I-6BI-199BI-311A
I-7AI-200AI-312A
I-10BI-201AI-313A
I-22AI-202BI-314A
I-23AI-203BI-315B
I-25AI-204AI-316B
I-26AI-208BI-318A
I-27BI-209BI-321A
I-29BI-212BI-327A
I-30BI-214AI-332B
I-35BI-215AI-333A
I-38BI-216AI-334A
I-40BI-217AI-335A
I-41AI-218AI-336A
I-45AI-219AI-346A
I-66AI-220BI-358A
I-82AI-221BI-359A
I-83BI-222BI-360B
I-84AI-225AI-362A
I-85AI-226AI-364A
I-87AI-229AI-366A
I-88BI-232BI-368B
I-91BI-234AI-369B
I-111BI-235AI-375A
I-112BI-239AI-376B
I-113BI-242AI-377A
I-114BI-250BI-378A
I-116BI-251AI-379A
I-122BI-255AI-380A
I-130AI-256AI-381A
I-131AI-258AI-388A
I-132AI-259AI-389B
I-133AI-260AI-394A
I-134AI-261BI-400A
I-135AI-263AI-404B
I-136BI-271AI-405A
I-141AI-272AI-406A
I-175AI-277BI-423A
I-176AI-279AI-424A
I-181BI-295AI-438A
I-183BI-296AI-457B
I-184AI-298AI-458A
I-185AI-299AI-461A
I-186AI-300AI-462B
I-188AI-301AI-465B
TABLE 69
Com-BiologicalCom-BiologicalCom-Biological
poundeffective-poundeffective-poundeffective-
No.nessNo.nessNoness
I-479AI-752AI-1088A
I-480AI-758AI-1090B
I-482AI-762AI-1093A
I-483AI-767BI-1094A
I-486AI-768AI-1095A
I-490AI-769AI-1096A
I-498AI-771AI-1098A
I-499AI-772AI-1103B
I-501AI-775AI-1104B
I-502AI-804AI-1106B
I-503AI-805BI-1123B
I-507AI-806BI-1147B
I-508BI-809B
I-510AI-818B
I-511AI-831B
I-514AI-839A
I-515AI-840B
I-516AI-872B
I-530AI-883A
I-531AI-885B
I-534AI-894B
I-543AI-895B
I-544AI-903B
I-545AI-904B
I-546AI-915A
I-550AI-958B
I-573BI-959A
I-580AI-960A
I-592AI-962A
I-595BI-964B
I-601AI-965A
I-667BI-967A
I-669BI-999A
I-670BI-1004A
I-671BI-1019A
I-672BI-1022A
I-675BI-1043A
I-682AI-1046A
I-683AI-1048A
I-690AI-1058A
I-692BI-1059A
I-693AI-1064B
I-694BI-1071A
I-695AI-1079B
I-704BI-1082B
I-705AI-1085A
I-726BI-1086B
I-731BI-1087A

Claims as granted

4 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

14 codes
IPC · International Patent Classification
Section A — Human necessities
  • A01P3/00
  • A01N43/54
  • A01N43/66
Section C — Chemistry; metallurgy
  • C07D251/46
  • C07D239/48
  • C07D251/44
  • C07D403/04
  • C07D251/42
USPC · US Patent Classification
514/241544/206544/207544/209544/217544/197

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJan 2000Jul 2000Jan 2001Jul 2001Jan 2002Jul 2002Jan 2003Jul 2003USPTOApplicantRestriction requirementNon-final rejectionNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
3.6 y
1,303 days filing → grant
Office actions
1
after a restriction
Responses
2
no RCE
Examiner
Richard L. Raymond
art unit 1624 · TC 1600
Citations: 17 back · 3 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom2002200420062008201020122014201620182020Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock